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Summary 
Pentraxins are fluid phase pattern recognition receptors phylogenetically 
conserved from arachnids to mammals. Based on the primary structure, pentraxins are 
divided in short pentraxins, like the C-reactive protein and the serum amyloid P, and 
long pentraxins, like PTX3. PTX3 is expressed by several cell types, including 
mononuclear phagocytes, myeloid dendritic cells, fibroblasts, smooth muscle cells 
and endothelial cells in response to pro-inflammatory cytokines and microbial 
components. This molecule is involved in innate immunity, tissue remodelling, 
female fertility and in tuning the inflammatory response. In particular, PTX3 plays a 
protective role in cardiovascular diseases (CVD), such as acute myocardial infarction 
(AMI) and atherosclerosis, in preclinical studies. Moreover, PTX3 has emerged as 
novel diagnostic and prognostic biomarker in CVD, reflecting the inflammatory 
involvement of the vascular bed. In AMI patients, PTX3 levels peak 6-8 hours after 
the onset of symptoms and in this context it balances pro-inflammatory and anti-
inflammatory stimuli. 
Since single nucleotide polymorphisms (SNPs) and microRNAs represent two 
ways in which gene expression can be modified/regulated, we addressed their role in 
the modulation of PTX3 expression. 
Given that PTX3 gene SNPs have been reported to be associated to different 
clinical conditions, in particular in innate resistance to infections, we assessed the role 
of PTX3 SNPs in affecting PTX3 plasma levels and CVD susceptibility. Despite the 
characterized role of PTX3 in inflammation, a regulation of PTX3 by microRNAs, 
which are fundamental fine-tuners of this process, has not yet been described. 
Therefore, we investigated the role of microRNAs in regulating PTX3 expression. 
 
To our first aim, we performed a candidate-gene association study on Caucasian 
subjects, in about 1500 healthy individuals and 1700 AMI patients. PTX3 plasma 
levels were measured by ELISA in healthy subjects as well as in AMI patients from 
GISSI-Prevenzione trial. Blood was collected from AMI patients at least 5 days after 
the last event. A significant difference in PTX3 levels was detected between AMI 
patients and controls, suggesting the persistence of high PTX3 plasma levels in AMI 
patients up to three months after the last event. Moreover, in AMI patients, PTX3 
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plasma levels significantly correlated with mortality, but not with cardiovascular 
death or reinfarction, confirming the prognostic value of this parameter previously 
described as an independent predictor of 3-months mortality in this pathological 
condition. Moreover, we report that the 3 PTX3 SNPs analysed (the intronic 
rs2305619 and rs1840680 and the exonic rs3816527), alone or combined in 
haplotypes, are associated with different PTX3 plasma levels. However, we did not 
find a correlation between the 3 SNPs analysed and the clinical condition of the 
subject. 
About our second aim, data reported in this thesis reveal the existence of a 
complex network of microRNAs able to down-regulate the basal as well as the TNFα- 
and IL-1β-induced PTX3 production. The effect of microRNA over-expression was 
evaluated through the transfection of synthetic pre-miR in the human 8387 
fibrosarcoma cell line, able to produce constitutively PTX3. The direct interaction 
miRNA:mRNA was evaluated through a luciferase reporter assay. Our results reveal 
that specific microRNAs, like miR-9 and miR-29, directly target and regulate PTX3 
mRNA. Other microRNAs, including miR-29, impair PTX3 expression acting on 
molecules of the signalling pathway that leads to PTX3 transcription. Among these 
miRNAs there are also miR-146a and miR-155, two of the major microRNAs 
involved in controlling the inflammatory response. Another microRNA, miR-181c, 
impairs PTX3 production by targeting key molecules involved in PTX3 induction and 
by directly acting on the messenger of ERp18, a molecule involved in PTX3 folding. 
In conclusion, our results underline the complexity of PTX3 regulation, revealing 
that both PTX3 SNPs and microRNAs are fundamental players of this process. 
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Introduction 
1- The pentraxin superfamily 
Pentraxins are pivotal components of the innate immune system that is a first line 
of resistance against pathogens. Innate immunity plays also a key role in the 
activation and orientation of adaptive immunity and in the maintenance of tissue 
integrity and repair1. 
Pentraxins form a superfamily of acute phase proteins with a distinctive 
multimeric organization. On the basis of the primary structure of the composing 
protomers, pentraxins are divided into two groups: short and long pentraxins. C-
reactive protein (CRP) and serum amyloid P (SAP) components are typical short 
pentraxins and they represent the main acute phase reactants in human and mouse, 
respectively2. PTX3 is the prototypic long pentraxin, a subfamily of pentraxins that 
are characterized by the presence of a long N-terminal domain, unrelated to other 
known proteins, associated with a C-terminal pentraxin-like domain. This last domain 
is 200 amino acid-long and it contains the conserved 8 amino acid-long pentraxin 
signature (HxCxS/TWxS, where x is any amino acid) (Fig. 1.1)3. 
Moreover, pentraxins are conserved in evolution from arachnids and insects to 
humans. Their conservation is testimony to their role in complex organisms. 
Structural analysis and genetically modified mice have provided a new level of 
understanding of the role of pentraxins in immunity and homeostasis. Unlike the 
classic short pentraxins CRP and SAP, whose sequence and regulation have diverged 
between mouse and human, PTX3 is highly conserved in human and mouse. Thus, 
results obtained using genetic approaches in the mouse are likely to be informative for 
the function of PTX3 in human1, whereas extrapolation from animals to human is 
more difficult for CRP and SAP4. 
Current literature suggests that short pentraxins are involved in the innate 
resistance to microbes and participate in the scavenging of cellular debris. On the 
other hand, studies performed on Ptx3-null mice have shown that this molecule has 
several functions in vivo. PTX3 acts as a soluble pattern recognition receptor (PRR) 
with a non-redundant protective role against selected pathogens and plays additional 
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roles at the crossroad between innate immunity, extracellular matrix (ECM) 
deposition and vascular biology2. 
Figure 1.1 | Short and long pentraxin structure. CRP and SAP belong to the short pentraxin 
subfamily and, like all pentraxins, are characterized by the presence of the pentraxin signature 
(HxCxS/TWxS, where x is any amino acid) in the 200 amino acid-long C-terminal domain. The N-
terminal domain, typical of long pentraxins, like PTX3, is not conserved among the members of this 
subfamily. Adapted from Garlanda et al.1. 
1.1 Short pentraxins 
The first pentraxin described was CRP, identified in human serum in the 1930s as 
the prototypic acute-phase response protein1,5. Human SAP was subsequently 
identified as a relative of CRP on the basis of amino acid sequence identity (51%)6. 
CRP and SAP orthologs in different mammal species share substantial sequence 
similarity; notable differences include serum basal levels and changes during the 
acute-phase response, with CRP and SAP being the main acute-phase reactants in 
human and mouse, respectively. 
1.1.1 Gene organization and expression 
The CRP gene is located on chromosome 1q23 and is organized in two exons, the 
first coding for the leader peptide and for the first two amino acids of the mature 
protein and the second coding for the remaining 204 amino acids. CRP levels in the 
plasma of healthy adults are barely detectable (≤ 3 mg/L), but they increase as much 
as 1000-fold following an acute-phase stimulus as a result of accelerated rates of 
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transcription in the liver, mainly in response to the proinflammatory cytokine IL-67. 
Expression of CRP mRNA in tissues other than the liver has also been reported, but 
apparently extra hepatic sources do not contribute to CRP plasma levels. CRP has 
been extensively used clinically for over 75 years as a nonspecific systemic marker of 
infection, inflammation, and tissue damage. 
SAP is produced exclusively by hepatocytes and is the main acute-phase protein 
in mice, whereas in human serum it is constitutively present at 30 to 50 mg/L. 
1.1.2 Protein structure 
Human CRP is composed of five identical non-glycosylated protomers with a 
total molecular weight of 115 kDa. The amino acid sequence includes two cysteines 
in positions 36 and 97 conserved in all the members of the pentraxin family and 
involved in intra-chain disulfide bonds8. 
SAP is a glycoprotein made up of five non-covalently attached subunits of 23 
kDa each. 
1.1.3 Ligand specificity, receptors and functions 
The physiological functions attributed to pentraxins involve recognition and 
binding to different ligands, mostly in a Ca2+-dependent manner. The relationship 
between ligand binding and function of pentraxins is a matter of debate. A list of 
selected ligands recognized by CRP and SAP is provided in Table 1.19. 
Table 1.1 | Main cellular sources and ligands of short pentraxins. Adapted from Bottazzi et 
al.50. 
Short pentraxins (CRP, SAP) 
Main cellular sources Ligands 
Liver (hepatocytes) 
- Complement components (C1q, Factor-H, L-ficolin, 
M-ficolin)  
 - Microorganisms (bacteria, viruses, fungi, parasites)  
 - Phosphorylcoline, carbohydrates 
 - Modified LDLs 
  
- ECM protein (fibronectin, collagen IV, laminin, 
proteoglycans) 
 - Amyloid fibrils 
  - DNA 
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The first ligand described for CRP was the C-polysaccharide of Streptococcus 
pneumoniae. This interaction is due to a direct binding of CRP to phosphorylcholine 
(PC), a major constituent of C-type capsule polysaccharides. Moreover, CRP binds 
various microorganisms, including fungi, yeasts, bacteria, and parasites (Plasmodium, 
Leishmania), through PC and carbohydrate structures, promoting phagocytosis and 
resistance to infections10. Binding to bacteria is not always necessary for protection 
because CRP also protects mice from infection with Salmonella typhimurium, a 
pathogen to which CRP does not bind11. Furthermore, CRP-mediated activation of the 
classical complement pathway (see below) has no role in protecting mice against S. 
pneumoniae infection12. 
Like CRP, SAP binds various bacteria, such as Streptococcus pyogenes and 
Neisseria meningitidis13. Moreover, binding to influenza virus has also been 
reported14. SAP binds to several bacteria via lipopolysaccharide (LPS) and prevents 
LPS-mediated complement activation and LPS toxicity13,15. However, for certain 
organisms to which SAP binds, such as S. pyogenes and rough strains of Escherichia 
coli, SAP enhances virulence by protecting the bacteria against phagocytosis, whereas 
it is protective in infection with organisms to which it does not bind, for instance 
Listeria monocytogenes13. 
CRP binds to modified low-density lipoprotein (LDL) via the PC and cholesterol 
moieties present on LDL16 and co-localizes with LDL in human atherosclerotic 
lesions17. However, CRP is neither atheroprotective nor proatherogenic in mouse 
models of human atherosclerosis4. 
Pentraxins recognize damaged cells and their constituents and are implicated in in 
vivo disposal of apoptotic cells. Human CRP binds to the membranes of damaged 
cells and apoptotic cells during late phases of apoptosis, via various phospholipids 
(PC and phosphoethanolamine) and small nuclear ribonucleoprotein particles and 
chromatin/nucleolar components that redistributes to the plasma membrane during 
late apoptosis7. Human SAP binds in vivo to chromatin18. 
CRP and SAP, aggregated or attached to most of their ligands, interact with the 
globular head of C1q, the recognition subunit of the classical complement pathway, 
and activate the classical complement cascade19. The three-dimensional structure of 
CRP shows the presence of a deep, extended cleft in each protomer on the face of the 
pentamer opposite that containing the PC-binding sites. Mutational analysis of 
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residues participating in the formation of this pocket identified the amino acids 
involved in C1q binding and complement activation20. 
Complement activation by short pentraxins may be one of the mechanisms 
leading to the removal of cellular debris21. When bound to self surfaces (e.g., 
apoptotic cells, damaged tissue), CRP activates the classical pathway of complement 
through interaction with C1q, but this activation is restricted to the initial stages with 
only little consumption of C5-C922. Furthermore, surface-bound CRP inhibits the 
alternative pathway amplification loop, possibly through the interaction with Factor 
H, the main soluble regulator of the alternative pathway of complement activation23. 
However, it is currently unclear whether this is a physiological phenomenon24. SAP 
binds to matrix components such as laminin, type IV collagen, fibronectin, and 
proteoglycans. Moreover, SAP binds to β-amyloid peptide in a Ca2+-dependent 
manner and contributes to the pathogenesis of amyloidosis25. 
A specific and saturable binding to all three classes of Fcγ receptors (FcγR) has 
been demonstrated for both CRP and SAP, and the interaction with FcγR is able to 
mediate phagocytosis of apoptotic cells and microorganisms, as well as mediate 
protective immune responses26,27. However, the interpretation of these data has been 
questioned28. The crystal structure of human SAP in complex with the extracellular 
domain of FcγRIIa has recently been characterized, indicating that the contact region 
between the two molecules involves the ridge helices of pentameric SAP. The 
functional activation of FcγR-mediated phagocytosis and cytokine secretion have 
been described. The stoichiometry of the interaction infers the requirement for 
multivalent pathogen binding for receptor aggregation29. These studies show that SAP 
and IgG share the binding site and compete for FcγR binding and that pentraxins 
inhibit immune complex–mediated phagocytosis. 
Thus, pentraxins possess similar functions to those of antibodies that activate 
both the complement and FcγR pathways. 
1.1.4 CRP plasma levels, the risk of coronary heart disease (CHD) and CRP 
genetic variations 
CRP is a nonspecific systemic marker of infection, inflammation, tissue damage 
and/or almost any form of adverse non-physiological stress. For this reason, an 
increased CRP concentration might reflect any of a very wide range of serious 
diseases which have not yet declared themselves, for example, Hodgkin’s disease or 
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renal carcinoma or any other condition which is often occult for some time before 
clinical presentation4. 
In healthy subjects CRP plasma concentration is usually within the range 0.1-3 
mg/L. However, after a strong acute stimulus (e.g. sepsis or AMI), it can rise by over 
1000-fold in 24-48 h and fall with a half time of about 24 h when the stimulus is 
removed4. Several population-based prospective studies of coronary heart disease 
(CHD) have reported an association between baseline CRP levels and CHD risk30,31. 
These observations, together with the reported ability of CRP to bind LDL16 and its 
presence in the atherosclerotic plaque17, have collectively raised the possibility that 
CRP may play a direct causal role in CHD (and, by implication, could be an important 
therapeutic target), although there is debate about the interpretation of both 
epidemiological and experimental observations32-34. 
Figure 1.2 | Types of association of a biomarker with a disease. The association between a 
biomarker (e.g., CRP) and a disease (e.g., atherosclerosis) may be represented by a causal relationship 
(causation: an increase in the biomarker as a consequence of the disease), by a reverse causation (the 
disease itself determines an increase of the biomarker), or by an association that is spurious because 
both the biomarker and the disease are affected independently by another known or unknown factor 
(confounding). Adapted from Schunkert et. al.38. 
The statistical strength of the association between CRP levels and CHD risk, 
derived from epidemiological studies, is at least as robust as that of established risk 
factors such as hypertension, diabetes mellitus, and hyper-cholesterolemia35. 
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However, statistical strength does not imply causality, since confounding factors or 
reverse causality offer alternative explanations for the association (Fig. 1.2). CRP is 
particularly susceptible to confounding, since multiple cardiovascular risk factors, 
including smoking, hypertension, obesity, lack of physical activity, and low 
socioeconomic status, all relate independently to elevated plasma levels of the 
protein36,37. Reverse causation is also a potential explanation, since atherosclerosis 
may trigger an elevation of CRP levels38. 
Since randomized trials of interventions, specific to CRP, have not yet been done 
in relation to cardiovascular disease outcomes, till now causality has been judged only 
with focused genetic studies39. 
Several single nucleotide polymorphisms (SNPs) within the CRP gene have been 
identified and four of them influence its circulating concentration40. CRP genotypes 
(and haplotypes) are clearly associated with CRP levels, but not with any of a large 
panel of established or emerging cardiovascular risk markers41. Indeed, CRP genetic 
variants responsible for changes in CRP plasma levels were used as an instrument for 
testing causality of CRP in atherosclerosis42. For doing that, scientists took advantage 
of the fact that persons are effectively randomly assigned at birth to either higher or 
lower CRP levels depending on the genetic variant they received from their parents. 
According to Mendel’s law of independent assortment, neither endogenous nor 
exogenous factors disturb this randomization process, which therefore can be termed 
“Mendelian randomization”43. This generalization is not entirely free of exceptions, 
since genes that are very close to one another on a chromosome do not segregate 
independently; however, it is probably true for most traits (Fig. 1.3)38. Once the 
quantitative association between CRP and CHD risk together with the quantitative 
correlation between CRP SNPs and CRP concentration were determined, scientists 
could predict the expected effect of the genetic variants on ischemic events. The 
observed association was markedly different from the predicted effect: none of the 
CRP variants were associated individually or in combination with the risk of ischemic 
events (Fig. 1.4)38,39,42. Taken together these data indicate that CRP concentration 
itself is unlikely to be even a modest causal factor in CHD39. 
Irrespective of the causal relevance of C reactive protein itself to CHD, however, 
there is considerable evidence that persistent inflammation might contribute to 
CHD39. Actually, the results of the large multicenter trial JUPITER have shown a 
remarkable reduction of cardiac events with rosuvastatin when compared to placebo 
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in about 18000 apparently healthy men and women, with normal LDL (<130 mg/dL) 
but CRP>2mg/L44. Though this is not a definite proof of the etiological role of 
inflammatory activation in cardiac disease, it extends the indication for preventive 
treatment aimed at decreasing CRP levels to a large class of subjects for whom there 
was not any indication in the past for a statin. 
Figure 1.3 | Conceptual diagram of a genetic “Mendelian randomization” experiment to 
judge the causal relevance of a biomarker associated with CHD risk. Adapted from Casas et al.4. 
Figure 1.4 | “Mendelain randomization” approach used for identifying the causal 
association between CRP and CHD. The mendelian randomization approach allows determination of 
a causal relationship between a biomarker and disease. It starts with the evidence that the biomarker is 
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associated with the disease (lower line of triangle). The quantitative nature of this association is 
determined. Genetic variants are then identified that affect the level of the biomarker (left line of 
triangle), and the quantitative nature of this relationship is also determined. Combining these two sets 
of information allows prediction of the effect of the genetic variant on disease risk if the association of 
the biomarker with the disease is causal. This prediction is then tested (right line of the triangle). If the 
predicted association of the variant with the disease is observed, then this would strongly suggest a 
causal relationship between the biomarker and the disease (since the relationship between the genetic 
variant and the disease can go in only one direction). If, on the other hand, no association is seen 
between the genetic variant and the disease, as observed for CRP, this would indicate that the 
association between the biomarker and the disease is due to either reverse causation or confounding. 
Adapted from Schunkert et. al.38. 
Is CRP mainly a causal risk factor in CHD, mainly a marker of established 
cardiovascular risk factors to which it is correlated, or mainly a marker of subclinical 
disease or some combination of these possibilities? This is an open question. A 
completely distinct possibility is that, in contrast to modest long-term differences in 
baseline CRP values, the major acute phase response of CRP triggered by AMI may 
contribute acutely to severity and outcome of the ischaemic lesion45. 
1.2 Long pentraxins 
PTX3 is the first member of the long pentraxin subfamily to be identified in the 
early 1990s as a new secreted protein rapidly induced by IL-1β in endothelial cells 
(ECs) or by TNFα in fibroblasts46,47.  
The long pentraxins identified after PTX3 include guinea pig apexin, neuronal 
pentraxin (NP or NPTX) 1 and NP2, also called NPTX2 or NARP, and NPTX 
receptor, which is the only member associated to the cell through a trans-membrane 
domain. NPTXs have been shown to be involved in the excitatory synaptic 
remodeling. NPTX2 has been implicated in long-term neuronal plasticity as well as 
dopaminergic nerve cell death and NPTX1 in hypoxia-ischemia and amyloid-b–
induced neuronal death. Recently, a search for pentraxin domain-containing 
sequences in different databases resulted in the identification of PTX4, a new long 
pentraxin, that, conserved among mammals, is also present in Xenopus laevis and 
zebrafish. PTX4 has a unique pattern of mRNA expression. For instance, its 
expression is high in the stroma of thymus and spleen and low in the brain and it does 
not behave as an acute phase gene48. 
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1.2 PTX3 
1.2.1 Gene organization and expression 
The human PTX3 gene (NCBI accession number: X7748; GI: 1679604) has been 
mapped on chromosome 3 (3q25) and is organized in three exons separated by two 
introns. The first two exons code for the leader peptide and the N-terminal domain of 
the protein and the third exon encodes the pentraxin domain. The murine gene 
presents the same structural organization and is located on chromosome 3. The PTX3 
gene shows high evolutionary conservation in sequence, gene organization and 
regulation, making it possible to address its pathophysiological roles in genetically 
modified mice. The proximal promoters of both human and murine PTX3 genes share 
numerous potential transcription factor binding sites including Pu1, AP-1, NF-κB, 
SP1 and NF-IL-6 sites. It has been shown that the NF-κB-binding site is essential for 
the transcriptional response to pro-inflammatory cytokines (e.g. TNFα and IL-1β), 
even if the SP1 site seems to have a role in this inducibility. On the other hand, AP-1 
controls the basal transcription of PTX349. 
PTX3 was originally identified as a cytokine-inducible gene in vascular 
endothelial cells (ECs) and fibroblasts. PTX3 expression is rapidly induced in a 
variety of additional cell types by several stimuli such as cytokines (e.g. TNFα and 
IL-1β), toll-like receptor (TLR) agonists, microbial moieties (e.g. LPS, outer 
membrane protein A, OmpA, and lipoarabinomannans) or intact microorganisms (Fig. 
1.5). Beside IL-1β and LPS, oxidized and enzymatically modified low-density 
lipoproteins (ox-LDL) promote PTX3 production in ECs and human primary vascular 
smooth muscle cells (SMCs). Similar inflammatory signals induce PTX3 expression 
in other cell types including myeloid dendritic cells (DCs), macrophages, kidney 
epithelial cells, synovial cells, chondrocytes, adipocytes, alveolar epithelial cells, glial 
cells, mesangial cells and granulosa cells50,51. PTX3 is constitutively stored in the 
specific granules of neutrophils and is released in response to TLR engagement by 
microorganisms or TLR agonists52,53. Expression of the PTX3 mRNA is temporally 
confined to immature myeloid cells. PTX3 can partially localize in neutrophil 
extracellular traps (NETs) formed by extruded DNA. In this context the neutrophil-
associated PTX3 promotes the generation of an antimicrobial micro-environment that 
is essential for trapping and killing microbes52. In contrast to these cell types, which 
express PTX3 upon stimulation, both human and murine lymphatic ECs constitutively 
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express the protein54. Resting T and B lymphocytes and natural killer cells do not 
express PTX3 mRNA. 
Figure 1.5 | Cellular sources and functions of the long pentraxin PTX3. PTX3 is produced by 
phagocytes (PMN, MΦ, myeloid DC), fibroblasts, SMCs, ECs and, to a lesser extent, by epithelial and 
mesenchymal cells, upon stimulation with microbial moieties (TLR agonists) or primary inflammatory 
cytokines (IL-1, TNF); IL-10 acts as a costimulus for proinflammatory stimuli. Once released, PTX3 
participates (i) in innate immune responses to fungi, bacteria, and viruses, through complement 
activation and regulation, microorganism opsonization, viral neutralization; (ii) in inflammatory 
responses, by modulating complement activation, by participating in the clearance of apoptotic cells, 
and possibly by other undefined mechanisms. PTX3 also participates in extracellular matrix deposition 
and angiogenesis. Adapted from Bottazzi et al.50. 
Interferon-γ inhibits PTX3 production in DCs, monocytes and macrophages by 
reducing both gene transcription and transcript stability, while IL-10 amplifies LPS-
induced PTX3 expression53,55. IL-4, dexamethasone, vitamin D3 and prostaglandin E2 
also inhibit LPS-induced PTX3 in myeloid DCs55. 
Different signalling pathways can affect PTX3 production, depending on cell 
type and/or stimuli. PTX3 expression in a model of acute myocardial ischaemia is 
controlled by the NF-κB pathway56, while induction of the protein by TNFα in lung 
epithelial cells does not require NF-κB, but rather involves the c-Jun N-terminal 
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kinase pathway57. Moreover, production of PTX3 in ECs that is induced by high-
density lipoproteins (HDL) requires the activation of the PI3K/Akt pathway through 
G-coupled lysosphingolipid receptors58. 
Glucocorticoid (GC) hormones induce or enhance PTX3 production in non-
haematopoietic cells (e.g. fibroblasts and ECs), but inhibit PTX3 production in 
haematopoietic cells (e.g. DCs and macrophages)59. These divergent effects are likely 
due to the fact that in non-haematopoietic cells, the GC receptor acts as a transcription 
factor, whereas in haematopoietic cells it interferes with the action of other signalling 
pathways, probably NF-κB and AP-1. 
1.2.2 Protein structure 
Human PTX3 is a multimeric glycoprotein, whose composing subunits are made 
of 381 amino acids, including a 17-residue signal peptide. PTX3 primary sequence is 
highly conserved among animal species. Like other members of the long pentraxin 
family, PTX3 is composed of a unique N-terminal region coupled to a 203-amino acid 
C-terminal domain homologous to the short pentraxins CRP and SAP60 (Fig. 1.1). The 
N-terminal region (residues 18–178 of the pre-protein) is unrelated to any known 
protein structure. Nevertheless, secondary structure predictions indicate that this part 
of the protein is likely to form four α-helices, three of which (amino acids 78–97, 
109–135 and 144–170) are probably involved in the formation of coiled-coil 
structures51. As stated above, the C-terminal domain of PTX3 (residues 179–381 of 
the pre-protein) is homologous to the short pentraxins CRP and SAP (57% 
similarity)60. Therefore, three-dimensional models of this domain have been generated 
that are based on the crystallographic structures of CRP and SAP and show the 
pentraxin domain of PTX3 to adopt a β-jelly roll topology, similar to that found in 
legume lectins (Fig. 1.6). A single N -glycosylation site has been identified in the C-
terminal domain of PTX3 at Asn22061. This site is fully occupied by complex-type 
oligosaccharides, mainly fucosylated and sialylated biantennary sugars with a minor 
fraction of tri- and tetrantennary glycans. Most importantly, PTX3 glycosylation has 
been shown to affect the protein binding to a number of ligands, thus suggesting that 
changes in the glycosylation status might represent a strategy to tune the biological 
activity of this long pentraxin (Fig. 1.7). 
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Figure 1.6 | Model of PTX3 octamer: arrangement of protomer subunits. (A) Schematic 
representation of the PTX3 protomer showing the N-terminal domain in yellow, followed by the 
globular pentraxin domain in red. Positions of the Cys residues, the N-glycosylation site at Asn220 and 
the pentraxin signature motif are indicated. Arrows point to a topological drawing of the N-terminal 
domain, which is believed to be composed of a globular region and three α-helical segments (α1, α2 
and α3), and a three-dimensional model of the C-terminal pentraxin domain based on the crystal 
structure of C-reactive protein (Protein Data Bank ID: 1b09). (B) Disulfide bond organization of the 
PTX3 octamer. The α-helical regions of the N-terminal domains in yellow are predicted to form coiled-
coil-like structures and hypothesized to adopt two distinct structural arrangements: either an extended 
conformation (right) in which four protomers associate through inter-chain interactions (i.e. to form 
tetramers) or a compact organization (left) where each protomer self-associates to form an antiparallel 
three-helix bundle (i.e. to form dimer of dimers). Cys317 and Cys318 in the C-terminal pentraxin 
domains (denoted in red) link the protomers (i.e. a tetramer and two dimers) into octamers. Adapted 
from Inforzato et al.2. 
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Figure 1.7 | Role of the two PTX3 domains in recognizing ligands. The overall molecule is 
necessary for optimal interaction with complement components (C1q and Factor H), microbial moieties 
(OmpA), and the extracellular matrix protein TSG-6. Recombinant N-ter domain can reconstitute the 
full-length protein in the interaction with IαI and FGF2. Interaction with conidia of A. fumigatus is also 
mediated by N-ter domain, whereas influenza virus and M-ficolin interact with the sialic acid present 
on the glycosidic moiety at Asn220, localized in the PTX domain. Adapted from Bottazzi et al.50. 
In addition to the multidomain organization, the human PTX3 protein shows a 
complex quaternary structure with eight protomer subunits held together by both 
covalent and non-covalent interactions60. In this regard, mass spectrometry and site-
directed mutagenesis analyses of the recombinant human protein indicate that cysteine 
residues at positions 47, 49 and 103 in the N-terminal region form three inter-chain 
disulfides holding four protein subunits in a tetrameric arrangement. Two tetramers 
are linked together to form an octamer by additional inter-chain bridges involving the 
C-terminal domain cysteines Cys317 and Cys318 (Fig. 1.6). A low-resolution model 
of the intact PTX3 molecule has been generated based on the data from electron 
microscopy and small-angle X-ray scattering (SAXS) that show that eight subunits of 
the protein fold into an elongated structure with a large and a small domain 
interconnected by a stalk region62. This oligomerization state and the asymmetric 
shape of the molecule make PTX3 unique among pentraxins. The only other pentraxin 
that forms an octamer is SAP from Limulus polyphemus, which has been reported to 
fold into a doubly stacked octameric ring. 
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As anticipated above, the structural determinants of the PTX3 quaternary 
organization are mainly localized in the N-terminal domain, where this region 
mediates the association of protomers into tetramers via both covalent (i.e. disulfide 
bonds) and non-covalent (i.e. inter-chain coiled coils) interactions62. Besides their 
structural role as building blocks of the PTX3 molecule, the N-terminal domain 
tetramers act as functional units in the recognition of PTX3 ligands. Therefore, the 
PTX3 quaternary structure plays a key role in dictating the protein-binding properties 
and, ultimately, its biological functions. 
1.2.3 Ligand specificity and receptors 
The physiological functions attributed to pentraxins involve recognition and 
binding to different ligands, including microbial moieties, complement components, 
P-selectin and ECM proteins (Table 1.2). 
Similarly to short pentraxins, PTX3 binds a number of selected bacteria, fungi 
and virus: a specific binding has been observed to conidia of Aspergillus fumigatus, 
Paracoccidioides brasiliensis and zymosan, to selected Gram-positive and Gram-
negative bacteria and finally to some viruses such as human and murine 
cytomegalovirus and influenza virus type A (IVA). The interaction between PTX3 
and IVA occurs through binding of sialylated oligosaccharides on PTX3 to the viral 
Table 1.2 | Main cellular sources and ligands of the long pentraxin PTX3. Adapted from 
Bottazzi et al.50. 
PTX3 
Main cellular sources Ligands 
Monocytes, MØ, PMN, EC, DC, 
fibroblasts, epithelial cells 
- Complement components (C1q, Factor-H, C4BP, L-ficolin, 
M-ficolin, MBL)  
  
- Microorganisms (bacteria, viruses, fungi) and microbial 
moieties (OmpA)  
  - ECM protein (IαI, TSG-6) 
  - Apoptotic cells 
  - FGF2 
 
haemagglutinin and results in the neutralization of virus infectivity in vitro63. 
Consistently, desialylated PTX3 does not bind IVA and does not neutralize virus 
infectivity. In addition to viral haemagglutinin, other microbial ligands have been 
identified. PTX3 binds OmpA from Klebsiella pneumoniae and amplifies the TLR2-
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dependent inflammatory response induced by OmpA after recognition of scavenger 
receptors LOX-1 and SREC-I. Pre-treatment with complement inhibitors abrogates 
PTX3 enhancement of OmpA pro-inflammatory effect, underlining the interplay 
among the cellular and the humoral arms of innate immunity in recognizing microbial 
moieties64. 
The interaction of PTX3 with the complement system has been known since the 
first characterization of the protein. PTX3 recognizes and modulates the activity of 
key components of all three-complement pathways (i.e. C1q, ficolins, mannose-
binding lectin (MBL), Factor H and C4b-binding protein (C4BP)]. PTX3 binds the 
first component of the classical complement cascade, C1q, interacting with the C1q 
globular head60. The interaction of PTX3 with plastic-immobilized C1q, an 
experimental condition that mimics the surface of microbes, results in the activation 
of the classical complement pathway. However, PTX3 inhibits the C1q haemolytic 
activity when the interaction occurs in the fluid phase, probably due to competitive 
blocking of relevant sites65. In addition, like CRP, PTX3 interacts with factor H, the 
main soluble regulator of the alternative pathway of complement, thus promoting 
factor H deposition on PTX3-coated surfaces and preventing exaggerated complement 
activation66. Moreover, PTX3 interacts with C4BP, a classical/lectin complement 
pathway inhibitor, enhancing its binding to apoptotic cells and recruiting functionally 
active C4BP to human fibroblast- and endothelial cell-derived extracellular matrices 
in vitro. This interaction probably prevents excessive local complement activation67. 
PTX3 also interacts with ficolin-268 and MBL69, thus enhancing complement 
deposition on A. fumigatus conidia and opsono-phagocytosis of Candida albicans by 
polymorphonuclear leucocytes, respectively. Finally, PTX3 binds M-ficolin and 
immobilized PTX3 is able to trigger M-ficolin–dependent activation of the lectin 
complement pathway70. 
Assessing the capacity of PTX3 to bind secreted cytokines and growth factors, it 
was found that PTX3 has a significant interaction with fibroblast growth factor 2 
(FGF2): PTX3 sequesters the growth factor in an inactive form, acting as a ‘FGF2 
decoy’ and tuning the neovascularization process71. 
PTX3 also interacts with ECM proteins such as TNFα-induced protein 6 (TSG-6) 
and inter-α-trypsin inhibitor (IαI). The binding of PTX3 to TSG-6 and IαI is essential 
for the correct organization of the viscoelastic matrix of cumulus oophorus and the 
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lack of PTX3 is associated with female subfertility as a consequence of cumulus 
matrix instability72,73. 
Although most of the ligands recognized by PTX3 require the full-length protein 
for optimal binding, the sites of interaction with both IαI and FGF2 are entirely 
localized in the PTX3 N-terminal domain51,73; this region of the protein is also 
responsible for the interaction of PTX3 with A. fumigatus conidia and factor H short 
consensus repeats 19–2066,74 (Fig. 1.7). Recombinant preparations of the N-terminal 
domain are endowed with the same functions as the full-length PTX3 with regard to 
organization of cumulus oophorus matrix and inhibition of FGF2-dependent 
proliferation of ECs51,73. 
The observation that macrophages display a binding site for PTX3 suggested the 
existence of a cellular receptor for this protein75. In the context of a study focused on 
SAP, Lu et al.29 recently reported that PTX3, similarly to CRP and SAP, can interact 
with Fcγ receptor (FcγR), in particular FcγRIII/CD16 and FcγRII/CD32, with Kd 1.6 
and 18.7 µM, respectively. In a parallel investigation, we observed a key role of CD32 
in the opsonic activity of PTX3 towards A. fumigatus74. It remains to be established 
whether PTX3 receptors other than FcγR exist. 
1.2.4 PTX3 function in innate immunity 
As stated above, PTX3 can interact with a number of different pathogens 
including selected fungi, bacteria and viruses. According to the binding properties, 
Ptx3-deficient mice are more susceptible than wild-type mice to infections caused by 
these pathogens. In particular, Ptx3-deficient animals are susceptible to A. fumigatus 
infection as a result of a defective recognition of conidia by alveolar macrophages and 
DCs. This susceptibility is associated with a low-protective T helper 1 (Th1) 
antifungal response coupled with an inappropriate Th2 response. Treatment with 
recombinant PTX3 restores the protective Th1 response showing that PTX3 can 
participate in the tuning of immune responses75. PTX3 interacts also with zymosan, a 
complex carbohydrate of the yeast cell wall that induces inflammatory signals in 
macrophages upon recognition by dectin-1, TLR2 and TLR6. PTX3 binding to 
zymosan promotes clearance of zymosan particles and zymosan-containing pathogens 
(i.e. P. brasiliensis) by macrophages in a dectin-1-dependent manner. In accordance, 
Ptx3-overexpressing mice have an increased phagocytic index towards the fungal 
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pathogen P. brasiliensis compared to wild-type animals and exogenous PTX3 can 
enhance the phagocytic activity of wild-type macrophages76. 
In the case of K. pneumoniae infection, overexpression of PTX3 by transgenic 
mice during infection was associated with an enhanced ability to produce pro-
inflammatory mediators, including nitric oxide (NO) and TNFα, and, as a 
consequence, with protection or faster lethality, depending on the dose of inocula.77 It 
is likely that, through its interaction with KpOmpA, PTX3 might modulate the pro-
inflammatory response triggered by K. pneumoniae64. 
Recent results indicate that PTX3 has therapeutic activity in chronic lung 
infections by Pseudomonas aeruginosa, which mimic lung infections of cystic 
fibrosis (CF) patients, by enhancing bacteria clearance, reducing the production of 
pro-inflammatory cytokines, neutrophil recruitment in the airways and 
histopathological lesions78. 
Bozza et al. found that upon binding to human and murine cytomegalovirus 
(MCMV), PTX3 reduced viral entry and infectivity in DCs in vitro. Consistently, 
Ptx3-deficient mice are more susceptible to MCMV infection than wild-type mice and 
PTX3 protects susceptible BALB/c mice from MCMV primary infection and 
reactivation in vivo79. 
Similarly, upon binding to influenza virus (H3N2), PTX3 inhibits virus-induced 
haemagglutination and viral neuramidase activity and neutralizes the virus infectivity 
in vitro and reduces mortality and the viral load in vivo in mice63. However, it has 
been recently reported that both seasonal and pandemic H1N1 influenza A viruses 
were resistant to the antiviral activity of PTX380. 
The molecular mechanisms underlying the opsonic activity of PTX3 have been 
recently investigated: PTX3 enhances the recognition and phagocytosis of conidia by 
neutrophils through an FcγRII-, CD11b- and complement-dependent mechanism74. 
1.2.5 PTX3 function in inflammation and cardiovascular disease 
The in vivo role of PTX3 in inflammatory conditions has been investigated using 
both Ptx3-overexpressing and Ptx3-deficient mice. PTX3 overexpression resulted in 
increased resistance to sepsis in the caecal ligation and puncture model81, but in 
increased mortality and inflammation in intestinal ischaemia and reperfusion injury82. 
In vivo models also showed that PTX3 is involved in modulating inflammation in 
sterile conditions, for instance, in acute myocardial infarction (AMI) and 
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atherosclerosis56,83(Fig. 1.8). Actually, as already mentioned, two of the main cellular 
components of the atherosclerotic lesion, namely ECs and macrophages, are major 
producers of PTX3 during inflammation. Accordingly, immunohistochemical staining 
showed a strong expression of PTX3 in advanced atherosclerotic lesions. PTX3 
immunoreactivity was observed in the ECM, ECs and macrophages within the lesion, 
as well as in subendothelial SMCs, neutrophils and in foam cells within lipid-rich 
areas of the plaque83. This is consistent with the observation that IL-1, LPS and ox-
LDL induce PTX3 production in cultured human SMCs. 
Figure 1.8 | The role of PTX3 in CVD. PTX3 is rapidly induced at the tissue level and released 
in plasma at sites of myocardial infarction, atherosclerosis, vascular damage or inflammation. The 
released protein interacts with different ligands and participates to the pathogenesis of CVD by 
modulating inflammation, complement activation, angiogenesis and restenosis. PTX3 also represents a 
useful diagnostic and prognostic biomarker in cardiovascular pathologies. 
In in vivo experiments56, PTX3 was observed to peak in the serum of wild-type 
mice after coronary artery ligation-induced ischaemia followed by reperfusion, similar 
to humans, and infarcts were significantly larger in Ptx3-deficient mice than in wild-
type littermates. It has been proposed that PTX3 might exert a protective 
cardiovascular role by modulating complement activation: in this context a higher 
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deposition of C3 was indeed observed in the infarct areas of Ptx3-deficient mice. 
Also, the interaction between PTX3 and factor H, which promotes deposition of factor 
H on PTX3-coated surfaces as discussed above, could represent a way to prevent 
tissue damage associated to excessive complement activation. Moreover, the finding 
that PTX3 binds P-selectin and attenuates neutrophil recruitment at sites of 
inflammation indicates that PTX3 may have in this context a regulatory role on 
inflammation by acting as a feedback mechanism of inhibition of leukocyte 
recruitment. Recent observations demonstrate that PTX3 binds to activated circulating 
platelets in AMI patients, dampening their proinflammatory and prothrombotic 
action84. All these findings suggest that PTX3 is endowed with a potential 
cardiovascular protective effect (Fig. 1.9), a view that is further supported by the 
recent observation that PTX3 deficiency enhances atherosclerosis in ApoE-/-mice and 
increases macrophage accumulation in the atherosclerotic lesions. In this animal 
model of atherosclerosis, the lack of PTX3 was associated with increased bone 
marrow monocytosis, which in turn was found to correlate with the extent of the 
lesion size. Furthermore, mice lacking PTX3 showed an increased expression of 
adhesion molecules, cytokines and chemokines in the vascular wall, thus suggesting 
that PTX3 may modulate the vascular-associated inflammatory response. Whether 
this effect is dependent upon vascular or bone-marrow-derived PTX3 remains to be 
addressed2,85. Since P-selectin deficiency in LdlR–/–86,ApoE–/–87, and wild-type88 mice 
attenuates the development of atherosclerosis, PTX3 protective function could derive 
from its ability to bind, via its N-linked glycosidic moiety, P-selectin, thus inhibiting 
leukocyte rolling on endothelium. Moreover, exogenously and endogenously 
administered PTX3 released from haematopoietic cells provide a negative feedback 
loop that prevents excessive P-selectin-dependent recruitment of neutrophils in a 
model of acute lung injury, pleurisy and mesenteric inflammation89. These data 
suggest that PTX3 produced by activated leukocytes might locally dampen neutrophil 
recruitment and regulate inflammation.  
In addition, both IL-4 and Th1-related cytokine interferon-γ inhibit LPS-induced 
PTX3 expression55. Second, anti-inflammatory molecules have been shown to induce 
PTX3 expression, including IL-10, which sustains LPS-mediated PTX3 expression in 
DCs55, GCs, which strongly induce the expression in ECs and fibroblasts59, and HDL, 
a class of molecules with anti-atherogenic properties, which induce PTX3 expression 
in vitro in human ECs and in vivo in C57BL/6J mouse aortas83. Furthermore, several 
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studies have clearly shown that efficient apoptotic cell clearance inhibits the 
inflammatory response and reduces the development of atherosclerosis and the size of 
the necrotic core. PTX3 binds apoptotic cells and regulates their clearance by antigen-
presenting DCs90. Also, through opsonization of apoptotic cells, PTX3 enhances C1q 
binding and complement-mediated clearance of the apoptotic debris21. Therefore, 
PTX3 may contribute to limiting the size and complexity of atherosclerotic lesions 
through both complement-dependent and independent mechanisms. All these data 
support the cardio- and athero-protective function of PTX3. 
In humans, PTX3 plasma levels predict 3-month mortality in patients with AMI91 
and increased tissue and plasma levels of PTX3 were also found in patients with non-
rheumatic aortic valve stenosis92, suggesting a role as diagnostic and prognostic 
biomarker. 
Figure 1.9 | PTX3 is endowed with a potential cardiovascular protective effect. 
1.2.6 PTX3 function in tissue remodelling and female fertility 
FGF2 is a major heparin-binding angiogenic inducer that promotes cell 
proliferation, chemotaxis and protease production in cultured ECs and 
neovascularization in vivo during wound healing, inflammation, tumour growth and 
atherosclerosis. PTX3 recognizes FGF2 with high affinity and specificity, where both 
proteins are produced by elements of the vessel wall (i.e. ECs and SMCs) during 
inflammation71,93. It is known that FGF2 exerts its activity by interacting with 
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tyrosine-kinase FGF receptors (FGFRs) and heparan sulfate proteoglycans (HSPGs) 
on the surface of ECs and SMCs, leading to formation of the proangiogenic 
HSPG/FGF2/FGFR ternary complex51. This process is inhibited by PTX3 in an 
experimental model of cell – cell adhesion71. The molecular mechanisms underneath 
the inhibitory activity of PTX3 are still unclear; however, recent observations indicate 
that PTX3 might function by blocking the FGF2–FGFR1 interaction rather than 
preventing the growth factor association with HSPGs. As a consequence of the 
HSPG/FGF2/FGFR complex inhibition, PTX3 suppresses the mitogenic activity 
exerted in vitro by FGF2 on cultured bovine, murine and human ECs. Consistent with 
this, PTX3 inhibits the FGF2-dependent angiogenesis in a number of in vivo animal 
models94. Therefore, PTX3 produced by ECs, SMCs and inflammatory cells may 
affect the autocrine and paracrine activity of FGF2 on endothelium and provide a 
mechanism for tuning the neo-vascularization process. Actually, the angiogenesis 
process (such as the generation of new blood vessels from the endothelium of existing 
vasculature) that occurs under normal physiological conditions in growth and 
development and is required for successful wound healing, is regulated by the balance 
between pro- and anti-angiogenic factors. 
A putative site of interaction with FGF2 has been identified in the region 97–110 
of the PTX3 N-terminal domain51 (corresponding to the segment between the first and 
second helices in Fig. 1.6). 
The PTX3–FGF2 interaction might also have important implications in the 
process of blood vessel narrowing that frequently occurs after percutaneous 
transluminal coronary angioplasty of atherosclerotic arteries. FGF2 is a key factor in 
restenosis, where it has been shown to promote survival, proliferation and migration 
of SMCs that express FGFRs51. PTX3 prevents the binding of FGF2 to FGFRs in 
human coronary artery SMCs, thus inhibiting the endogenous FGF2-dependent SMCs 
proliferation and suppressing the mitogenic and chemotactic activities exerted by 
exogenous FGF2 on these cells93. These observations suggest a novel therapeutic role 
of PTX3 in the treatment of restenosis after angioplasty2. 
An increasing body of evidence points to PTX3 as an important component of the 
ECM with novel functional implications in tissue remodelling. Indeed, PTX3 is 
produced by mouse cumulus cells during cumulus expansion and has been shown to 
localize within the matrix, playing a non-redundant role in in vivo fertilization. In this 
regard, Ptx3−/− mice generated by homologous recombination display a severe 
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deficiency in female fertility. This subfertility has been attributed to defective 
assembly of the viscoelastic HA-rich matrix that forms around the oocyte in the pre-
ovulatory follicle (namely, the cumulus oophorus complex), where correct deposition 
of cumulus matrix is necessary for fertilization in vivo. The major component of the 
cumulus matrix is HA, which is produced by cumulus and granulosa cells72. Besides 
PTX3, other molecules are required for effective incorporation of the newly 
synthesized HA into the matrix, including the HA-binding protein TSG-6 and the 
serum proteoglycan IαI. In fact, genetic or functional deletion of IαI or TSG-6 leads to 
impaired cumulus matrix formation and severe subfertility, a similar phenotype to that 
observed in Ptx3−/− mice95. Current literature supports the hypothesis that heavy 
chains (HCs) from IαI become covalently attached to HA (i.e. to form HC•HA 
complexes) through reactions involving TSG-6, which acts as both a cofactor and 
catalyst. The resulting HC•HA complexes are believed to be crosslinked by PTX3, 
where the long pentraxin can establish multiple contacts to HCs, thus providing 
structural integrity to the cumulus matrix. Implicit in this model is the concept that 
PTX3 has a nodal activity that is dependent on its multimeric organization. Consistent 
with this, the protein tetramer is the functional molecular unit required for matrix 
organization. Accordingly, recombinant preparations of the PTX3 N-terminal domain 
(i.e. that forms tetramers and contain the HC-binding site) have been proved to sustain 
assembly of the cumulus matrix73,96. 
1.2.7 PTX3 levels in immune and inflammatory disorders and CVD 
CRP has been extensively used clinically for over 75 years as a non-specific 
systemic marker of infection, inflammation and tissue damage. The structural and 
functional relationship to CRP, now experiencing a renaissance in cardiovascular 
disorders, and the data obtained in gene-modified mice have prompted studies aimed 
to assess the usefulness of PTX3 in diverse human pathological conditions. The 
hypothesis driving much of previous and ongoing efforts is that PTX3, unlike CRP 
(i.e. made in the liver and induced primarily by IL- 6), may represent a rapid marker 
for primary local activation of innate immunity and inflammation. Indeed, in all 
clinical studies conducted so far, the correlation between levels of PTX3 and CRP 
was loose or non-significant. A second general characteristic emerging from studies 
of blood levels in murine and human pathology is the rapidity of PTX3 increase, 
compared to CRP, consistent with its original identification as an immediate early 
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gene. In man and mouse PTX3 behaves as an acute phase protein because its blood 
levels, low in normal conditions (about 25 ng/ml in the mouse, <2 ng/ml in humans), 
increase rapidly (with a maximum at 6–8 h) and dramatically (200–800 ng/ml) during 
endotoxic shock, sepsis and other inflammatory and infectious conditions. Increased 
levels of PTX3 have been observed in diverse infectious disorders including sepsis 
and septic shock, meningococcal disease, tuberculosis (TB) and dengue infection. In 
some of these cases a significant correlation was found between PTX3 plasma levels 
and severity of disease83. 
Increased levels of PTX3 have been observed in a restricted set of autoimmune 
disorders (e.g. in the blood in small vessel vasculitis and psoriasis and in the synovial 
fluid in rheumatoid arthritis). In small vessel vasculitis, PTX3 levels correlate with 
clinical activity of the disease and represent a candidate marker for monitoring its 
progression90. 
Patients with chronic kidney disease (CKD) also show increase in PTX3 plasma 
levels, with the highest concentrations observed in the group of patients with a more 
severe disease. Moreover, patients with high PTX3 levels had higher all-cause 
mortality and cardiovascular mortality, suggesting that PTX3 could have a predictive 
value of mortality in CKD patients97. It has been reported that the concentration of 
circulating PTX3 increases during pregnancy, a condition that is associated with 
inflammation. Higher maternal PTX3 levels have been observed in pregnancies 
complicated by preeclampsia, which represents the clinical manifestation of an 
endothelial dysfunction that is part of an excessive maternal inflammatory response to 
pregnancy98,99. PTX3 plasma and vaginal levels increase also during pregnancy 
complicated by spontaneous preterm delivery, in particular in cases of placenta 
vasculopathy100. Furthermore, recent studies have reported the presence of PTX3 in 
the amniotic fluid and elevated protein concentrations in intra-amniotic inflammation 
and infection. In contrast, the increased titres of maternal plasma PTX3 observed 
during labour are not related to either intra-amniotic inflammation or infection101. 
Vessel wall elements (e.g. ECs and SMCs) produce high levels of PTX3 during 
inflammation. Given the homology to CRP, the prognostic and diagnostic relevance 
of PTX3 has been investigated in cardiovascular pathology. In this regard, a number 
of evidences point to PTX3 as a useful marker of vascular integrity, including the 
observations that high levels of PTX3 are seen in the heart and vascular cells in 
response to inflammatory signals and ox-LDL and the protein is present in 
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atherosclerotic lesions83. According to this, PTX3 has emerged from several studies as 
a new candidate prognostic marker in ischaemic heart disorders such as AMI. PTX3 
levels increase rapidly in AMI, reaching a peak at around 7 h after the onset of 
symptoms and do not correlate to those of CRP. Compared with established markers 
(i.e. CRP, N-terminal pro-brain natriuretic peptide and troponin T), PTX3 has been 
proposed as the only independent predictor of 3-month mortality in a cohort of 748 
patients with AMI and ST elevations91. In AMI, immunostaining for PTX3 was 
observed within and around ischaemic lesions. In early ischaemic lesions, PTX3 was 
expressed primarily by granulocytes; in more advanced AMI, PTX3 positivity was 
found in the interstitium and in the cytoplasm of macrophages and the endothelium102. 
Recently, a flow cytometric analysis suggested that in the early phase of AMI (within 
6h from the onset of symptoms) circulating neutrophils release preformed PTX3, 
whereas 48h after the onset of symptoms neutrophil PTX3 returns to normal values84. 
Furthermore, PTX3 is present and localized within and around histological lesions in 
infectious myocarditis102. 
In a recent prospective study, the correlation of circulating levels of PTX3 to 
incident CVD in older adults with no clinical symptoms of CVD has been 
investigated. PTX3 was found to associate with CRP but not with SAP, and with 
some CVD risk factors (i.e. age, fasting glucose and insulin) and the presence of 
subclinical CVD. Moreover, PTX3 correlated with CVD death and all-cause death, 
similarly to CRP. However, unlike CRP, PTX3 associated only with fatal events103. 
Therefore, PTX3 and CRP may reflect different aspects of inflammation in 
atherosclerosis and perhaps other vascular diseases. 
Also heart failure (HF) is characterised by higher than normal circulating 
concentrations of inflammatory cytokines and CRP. PTX3 levels are higher in 
patients with HF than in healthy controls, increase with severity of HF and, more 
interestingly, are independent predictors of the disease outcome. These findings have 
been extended in two studies that reported a better prediction of HF risk when three 
biomarkers (i.e. brain natriuretic peptide, heart-type fatty acid-binding protein and 
PTX3) were combined. Moreover, in the GISSI-HF trial PTX3 was measured at 
baseline in 1233 patients with chronic HF and found elevated in patients with more 
severe disease, in particular, in those with advanced age, ventricular dysfunction, 
worse symptoms and co-morbidities such as atrial fibrillation or diabetes91. 
Introduction 
 
	   30	  
Circulating PTX3 levels are significantly elevated in patients who undergo 
percutaneous coronary intervention and in those with unstable angina, thus suggesting 
that PTX3 may be a candidate marker to predict occurrence of unstable angina104. 
PTX3 has also been proposed as a useful marker for evaluation of inflammatory 
reaction and neointimal thickening after vascular injury105. 
In conclusion, it is likely that PTX3 act as a molecule at the crossroad between 
pro-inflammatory and anti-inflammatory stimuli, perhaps by balancing the over-
activation of a pro-inflammatory, pro-atherogenic cascade. PTX3 may represent a 
useful marker of cardiovascular pathology complementary to CRP: being directly 
produced by damaged tissues, its increase precedes CRP and rapidly reflects the 
vascular involvement by inflammatory process. In particular, the combination of 
PTX3 and classical biomarkers showed an incremental diagnostic and prognostic 
value in several conditions, including sepsis, acute coronary syndromes and chronic 
heart failure. These data suggest that PTX3 is a novel promising biomarker to provide 
useful prognostic information for clinical outcomes in these pathologic conditions106. 
1.2.8 PTX3 genetic variations in innate immunity and fertility 
Despite its strong evolutionary conservation, recent studies have reported a 
certain number of single-nucleotide polymorphisms (SNPs) in the PTX3 gene, 
summarized in Table 1.3. 
In line with the structural and functional conservation of the gene, most of these 
genetic variations were found in the non-coding regions and only one of the two 
described exon substitutions result in amino acid variation of the protein. 
Interestingly, some of these polymorphisms, especially when associated in 
specific haplotypes, have been related to clinical conditions including infections and 
fertility. 
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Table 1.3 | PTX3 single nucleotide polymorphism information. 
SNP ID (rs) Position (bp) Localization Alleles Peptide shift 
rs35948036 157154768 Exon 1 T/C p.Leu16= 
rs2305619 * 157154861 Intron 1 G/A  
rs3816527 * 157155314 Exon 2 A/C p.Asp48Ala 
rs1840680 * 157156029 Intron 2 G/A  
rs3845978 157159694 Intron 2 C/T  
rs2614 157160999 3'UTR C/T  
rs6788044 157167340 
About 6 kb 
downstream the 
3'UTR (intron 4 of 
VEPH1 gene) 
T/C   
*The GAG haplotype (rs2305619, rs3816527, rs1840680 SNPs) is protective in M.tuberculosis 
and P.aeruginosa infections and it is associated with increased female fertility and LPS-induced PTX3 
production. 
In 2007, Olesen et al. investigated the role of PTX3 genetic variations in affecting 
host vulnerability to pulmonary tuberculosis (TB) in West Africans from Guinea-
Bissau107. This article has been the first work on PTX3 polymorphisms and the 
authors demonstrated a difference in PTX3 haplotype frequencies between cases 
(N=321) and controls (N=347), revealing a protective effect of a specific haplotype 
against TB. In particular, they studied 5 PTX3 SNPs, spanning the 6.7 kb length of the 
gene: rs2305619, rs3816527, rs1840680, rs3845978, rs2614. Among these SNPs, 
rs2305619 and rs1840680 showed significant difference between TB cases and 
controls for both allelic and genotypic distributions using an uncorrected p-value of 
0.05. However, none remained significant after Bonferroni’s correction. The GAG 
haplotype, corresponding to rs2305619, rs3816527 and rs1840680 SNPs, showed a 
significant higher frequency in the control population compared to cases (46.2% vs 
36.5%; p=0.0281; OR=0.782), demonstrating a protective effect relative to other 
haplotypes. The authors did also an LD analysis within PTX3 gene using the 
HaploView software. The LD structure in PTX3 appeared different between cases and 
controls, with controls having a smaller block size, suggesting either a more recent 
origin of the case haplotype or a selection maintaining a larger block structure. Data 
indicating that PTX3 SNPs affect the susceptibility to pulmonary TB and PTX3 levels 
correlate with disease activity in West African subjects108 suggest the relevance of this 
molecule in innate resistance to TB. 
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In 2010, Chiarini and colleagues studied the role of PTX3 polymorphisms in the 
development of chronic Pseudomonas aeruginosa (PA) airway colonization in 
patients with cystic fibrosis (CF)109. The analysis has been conducted in 127 CF 
Caucasian patients homozygous for F508del (age ≥ 11 years) and on five SNPs in 
PTX3 gene, three intronic (rs2305619, rs1840680 and rs3845978) and two exonic 
(rs35948036 and rs3816527). Statistical analysis has shown that the intronic SNPs 
rs2305619 and rs1840680 and the exonic rs3816527 are statistically associated (χ 2-
test: p=0.012, p=0.016, p=0.038 respectively) with PA colonization. However, after 
permutation test, PA colonization was significantly associated only with rs2305619. 
The authors included in the haplotype analysis the three SNPs associated with PA 
colonization. The GAG haplotype was present in the 58.7% of non-PA patients and in 
the 42.7% of PA patients (P=0.012). After permutation test, the GAG haplotype 
preserved a significant p-value (0.030). The linkage disequilibrium (LD) analysis 
within PTX3 gene revealed that LD structure in PTX3 is not different in patients with 
or without PA colonization. The clinical outcome of pulmonary disease in CF patients 
is extremely variable, even among patients with the same CFTR genotype. This 
variability could arise from some combination of environmental and modifier gene 
effects. As the association between PTX3 haplotypes and PA infections in CF patients 
suggests, PTX3 seems to be involved in preventing lung colonization by this 
opportunistic pathogen. 
Since in the mouse PTX3 plays an important role in the formation of the extracellular 
matrix of the cumulus oophorus in ovarian follicles, as well as implantation and 
decidualization72,110,111, May et al. tried to understand whether PTX3 genetic variants 
could influence female fertility112. To study the natural fertility of women the authors 
conducted the study on subjects from a rural area of Ghana, where the population 
lives under adverse environmental conditions and the use of contraceptives has been 
virtually absent. In this association study, 17 SNPs, from HapMap database, in PTX3 
gene and in its flanking regions have been analysed for their potential relationship 
with the ex-vivo LPS-induced PTX3 production and female fertility. The ex-vivo LPS-
induced PTX3 production was associated with fertility (p=0.040): women who had 
more than 11 children had highest PTX3 production. The same observation has been 
done in postmenopausal women, in which fertility can best be observed because 
reproduction has terminated. No differences have been found in PTX3 production for 
women with 3-11 children. Six out of the 17 genotyped SNPs have been found to be 
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associated with either higher or lower LPS-induced PTX3 production. Among them, 
the only polymorphism mapped within PTX3 gene is rs3816527: the variant allele 
carriers (C) have a higher PTX3 production than noncarriers (p=0.035). The strongest 
association was observed for the rs6788044 SNP that is located in intron 4 of VEPH1 
gene, 6 kb downstream PTX3 gene: variant allele carriers (C) had significantly higher 
PTX3 production after LPS stimulation than noncarriers (p=0.003). Genetic variants 
associated with higher LPS-induced PTX3 production were also associated with a 
higher number of offspring and vice versa. The rs6788044 SNP associated 
significantly with higher PTX3 production as well as the amount of offspring 
(p=0.043). The previously studied GAG haplotype was associated with an increased 
PTX3 production (p=0.080) and an increased number of offspring (p=0.011). May et 
al. provided the first evidence that PTX3 plays a role in female fertility in humans. 
Results from these association studies suggest that genetic variants in PTX3 are 
associated with different susceptibility to M.tuberculosis and P.aeruginosa infections 
and to fertility as well as different levels of ex-vivo LPS-induced PTX3 production. 
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2- Genetics of complex diseases 
2.1 The role of SNPs in susceptibility to complex common diseases 
The major impact of genetics on medicine has been so far the identification of 
visible chromosomal defects and mutations that interfere with the function of a single 
gene. Diseases caused by these rare variations in a single genetic locus are termed 
‘Mendelian’ or ‘single gene’ disorders. They exhibit one of the following 
characteristic patterns of transmission: autosomal dominant, autosomal recessive, X-
linked, mitochondrial. On the other hand, most common disorders with adult onset 
show familial aggregation that usually exhibits a complex inheritance, which is 
characterized by the additive effects of variations in one or more genes and/or 
environmental risk factors. Such conditions include for example atherosclerosis, 
hypertension, hypercholesterolemia, diabetes, obesity and several cancers (Fig. 
2.1)113. 
Figure 2.1 | Multifactorial aetiology of complex diseases. The susceptibility to complex 
diseases is given by the combination of genetic and environmental risk factors that, interacting each 
other, increase the risk of developing such a disease. 
Every person in the world, with the exception of identical twins, has a unique 
genome that shares a 99.9% of identity with the genome of another person. 0.1% of 
diversity means millions of nucleotide variations among the 3.2 billion base pairs of 
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the whole human genome. Most of these variations take the form of Single Nucleotide 
Polymorphisms (SNPs), even if genetic variations include also deletions, insertions 
and Copy Number Variations (CNV). A SNP is traditionally defined as a variation in 
DNA sequence that involves only a single nucleotide and that occurs in the population 
with a minimal frequency of 1% (MAF >1%). These type of genetic variants are 
expected not only to account for phenotypic variations among individuals, but also for 
the susceptibility to above-mentioned complex diseases114. 
Probably mutations that cause strongly deleterious phenotypes - as most 
Mendelian diseases appear to be - are lost because of natural selection. Conversely, 
variants conferring an advantage are often the basis for evolutionary change and tend 
to rise rapidly to high frequency, a phenomenon known as genetic hitchhiking115. 
Although the majority of neutral variants, like polymorphisms are often supposed to 
be, are lost by chance, a minority of them eventually become fixed in the 
population116. 
The “common disease–common variant” (CD-CV) hypothesis postulates that 
common polymorphisms (MAF >1%) that have low penetrance might contribute to 
susceptibility to common diseases117-119. Actually, common diseases often have late 
onset, with modest or no obvious impact on reproductive fitness120. Moreover, some 
alleles that were advantageous or neutral during human evolution might now confer 
susceptibility to disease because of changes in living conditions accompanying 
civilization. Finally, disease-associated alleles could be maintained at high frequency 
if they were under balancing selection, being responsible for a beneficial phenotype 
(as in sickle-cell disease and malaria resistance). The concept was not that all disease-
associated variants at these genes should be common, only that some common 
variants exist and could be used to pinpoint loci for detailed study121. 
It took a decade to develop the tools and methods required to test the CD-CV 
hypothesis: (i) catalogues of millions of common variants in the human population, 
(ii) techniques to genotype these variants in studies with thousands of patients (e.g. 
Genome-Wide Association Studies, GWAS), and (iii) an analytical framework to 
distinguish true associations from noise and artefacts122. 
GWAS are proving adept at identifying common variants contributing to the 
inherited component of common diseases. Almost all such variants seem to have 
modest effect sizes and, even when combined, their impact on overall population 
variance and predictive power is limited. There is a marked disparity between the 
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extent of overall familial aggregation observed for many common diseases and that 
attributable to variants identified to date. Although the identification of additional 
common risk variants will explain some of this deficit, one hypothesis anticipates that 
a significant proportion of this ‘missing heritability’ will be attributable to low-
frequency variants with intermediate penetrance effects, which have been largely 
refractory to conventional gene-discovery approaches (Fig. 2.2)123. Whereas rare 
variants are more likely to be restricted to specific ethnic groups124,125, common 
variants (perhaps 90% of heterozygous sites in each individual) are typically shared 
among continental populations122. 
Figure 2.2 | Low-frequency variants and disease susceptibility. Adapted from McCarthy et 
al.123. 
It is important to observe that, usually, each disease-associated variant bears a 
specific set of common alleles in cis at nearby loci (tag SNPs). When considered 
together, all these SNPs form the so-called “haplotype”. This means that genotypes of 
common SNPs could be inferred from knowledge of only a few empirically 
determined tag SNPs126-128. Because the recombination rate is low (~1 crossover per 
100 Mb per generation), disease alleles in the population typically show association 
with nearby marker alleles for many generations, a phenomenon termed linkage 
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disequilibrium (LD) (Fig. 2.3)122. Actually, when an association between disease 
susceptibility and a specific SNP is observed, the LD with nearby SNPs has to be 
considered. 
Figure 2.3 | DNA sequence variation in the human genome. Common and rare genetic 
variations in 10 individuals, carrying 20 distinct copies of the human genome. The amount of variations 
shown here is typical for a 5-kb stretch of genome and is centered on a strong recombination hotspot. 
The 12 common variations include 10 SNPs, an insertion-deletion polymorphism (indel), and a 
tetranucleotide repeat polymorphism. The six common polymorphisms on the left side are strongly 
correlated. Although these six polymorphisms could theoretically occur in 26 possible patterns, only 
three patterns are observed (indicated by three different brown shades). These patterns are called 
haplotypes. Similarly, the six common polymorphisms on the right side are strongly correlated and 
reside on only two haplotypes (indicated by two different blue shades). The haplotypes occur because 
there has not been much genetic recombination between the sites. By contrast, there is little correlation 
between the two groups of polymorphisms, because a hotspot of genetic recombination lies between 
them. The pairwise correlation between the common sites is shown by the red and white boxes below, 
with red indicating strong correlation and white indicating weak correlation. In addition to the common 
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polymorphisms, lower-frequency polymorphisms also occur in the human genome. Five rare SNPs are 
shown, with the variant nucleotide marked in red and the reference nucleotide not shown. In addition, 
on the second to last chromosome, a larger deletion variant is observed that removes several kilobases 
of DNA. Such larger deletion or duplication events (i.e., CNVs) may be common and segregate as 
other DNA variants. Adapted from Altshuler et al.122. 
The International HapMap Project was launched in 2002, with the goal of 
characterizing SNP frequencies and local LD patterns across the human genome in 
270 samples from Europe, Asia, and West Africa. The project genotyped ~1 million 
SNPs by 2005129 and more than 3 million by 2007130. 
SNPs, that are located within coding or regulatory regions of a gene, may directly 
influence phenotype. In fact, when the variation is found in the coding sequence of a 
gene, it may alter the primary structure and the function of the encoded protein and 
this could result in a disease manifestation, sometimes with high penetrance. On the 
other hand, SNPs within regulatory regions tend to have more quantitative effects, for 
example by altering the expression level of the protein. However, the majority of 
SNPs are situated in noncoding regions of the genome (Fig. 2.4)113. 
Figure 2.4 | Schematic illustration of SNP types. A SNP in the promoter region of a gene can 
alter transcription by modifying the binding of specific transcription factors to their binding sites. 
Within the coding sequence of the gene synonymous SNPs are variations that do not alter the primary 
structure of the protein, whereas missense SNPs alter a codon, resulting in an amino acid change. The 
insertion or deletion of a nucleotide in the DNA sequence shifts the reading frame (frameshift) and 
disrupts the transcription of the remaining sequence. Sometimes a SNP in the coding sequence of a 
gene can result in the generation of a premature stop codon. Adapted from Ho et al.113. 
Noncoding mutations with roles in disease susceptibility will likely open new 
doors to understanding genome biology and gene regulation. Regulatory variation 
also suggests different therapeutic strategies: modulating levels of gene expression 
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may prove more tractable than replacing a fully defective protein or turning off a 
gain-of-function allele122. 
The association of genetic variants to disease susceptibility provides, on one 
hand, the opportunity to predict the risk of disease and, on the other hand, novel 
insights about the mechanism of the disease. The more disease pathways are known, 
the more prediction, prevention, diagnosis, prognosis and treatment can be improved 
(Fig. 2.5). 
Figure 2.5 | Clinical translation of identified new susceptibility variants. Adapted from 
McCarthy et al.123. 
2.2 Coronary artery disease as a complex trait 
Cardiovascular disease (CVD) is the leading cause of mortality in many 
countries, accounting for 16.7 million deaths each year131,132. Coronary artery disease 
Introduction 
 
	   40	  
(CAD) and cerebrovascular disease are the most common forms of cardiovascular 
disease, and they have severe consequences both for the individual person and society 
at large. Their underlying pathological process is atherosclerosis, a slowly progressing 
chronic disorder of large and medium-sized arteries133. For many years it was 
believed that atherosclerosis was merely passive accumulation of cholesterol in the 
vessel wall. Today, the picture is much more complex, with atherosclerosis being 
thought of as a chronic inflammatory disease134. 
CAD has long been known to ‘run in families’. A small proportion of cases can 
be attributed to rare, highly penetrant, monogenic effects, but most are multifactorial 
in aetiology, involving numerous environmental and heritable risk factors. 
Molecular genetic studies have identified few mutations that cause premature 
CAD (Table 2.1). The same studies revealed the heritable basis of several 
atherosclerosis risk factors (e.g. LDL and HDL cholesterol), which are presumed to 
explain a fraction of an individual’s inherited risk for common CAD. However, most 
genes involved in susceptibility to multifactorial CAD are unknown134. In fact, many 
studies demonstrated that a family history of CAD/AMI is an independent predictor of 
CAD risk, even after adjustment for several classical risk factors (sex, age, smoking, 
LDL and HDL cholesterol and blood pressure)135,136. 
Table 2.1 | Mendelian diseases that involve premature coronary artery disease. Adapted from 
Watkins et al.138. 
Disease Genes Effect of mutations OMIM number 
Familial 
hypercholesterolaemia LDLR Defective binding of LDL by receptor #143890 
Familial defective 
APOB APOB 
Reduced binding affinity of APOB to 
LDLR #144010 
Autosomal recessive 
hypercholesterolaemia ARH Defective endocytosis of LDLR #603813 
APOA1 deficiency APOA1 Deletion or loss-of- function mutation that leads to very low HDL #107680 
Tangier disease ABCA1 Impaired cholesterol efflux in macrophages (foam cells) #205400 
Homocystinuria CBS Homocysteine increases thrombotic tendency #23620 
 
Although a family history of CAD is considered a classical risk factor, it is 
complex to associate the individual genetic background to the risk of developing 
atherosclerosis and subsequently Acute Myocardial Infarction (AMI)113. We are 
probably far from the possibility to quantify the risk to develop atherosclerosis or 
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AMI based on the genetic fingerprint, but this type of information could be useful for 
stratifying the population and perform a primary prevention and for improving our 
understanding of its pathogenesis. 
Notably, the genetic architecture of CAD susceptibility is extremely complex. 
First, the list of known risk factors is long and many of these traits have their own 
complex genetic basis. Second, CAD is rare before the age of 50 years, and is 
therefore confined to aged populations. Consequently, it can be considered an entirely 
modern disease not directly subjected to selective pressure as it is unlikely to have an 
effect on reproductive success. Variants that confer either susceptibility or protection 
to CAD might therefore have evolved neutrally in the past137. It is possible that CAD-
associated variants have pleiotropic effects, thus affecting the susceptibility to more 
‘ancient’ diseases (for example, infectious disease)138. 
The strategies used to study the genetic factors of CAD have evolved rapidly in 
recent years due to advances in high-throughput genomic technologies, sharing of 
data in large scale consortia129, and statistical genomics. Two different approaches can 
be used for investigating the genetic basis of CAD: linkage analysis and association 
studies. The genes identified through these combined approaches have diverse 
functions: they include transcription factors that are implicated in vasculogenesis, 
signalling molecules that are involved in inflammation, innate and adaptive immunity, 
and novel apolipoproteins, as well as genes for which the physiological roles are as 
yet unclear138. 
2.2.1 Linkage analysis 
A linkage analysis is based on the assumption that a genetic linkage exists 
between disease-associated variations and common polymorphic variants, named 
“markers”. These variations are shared by affected individuals in a large pedigree (in 
which the disease of interest is prevalent) more often than predicted by Mendelian 
segregation or chance. The probability that the marker and a CAD susceptibility locus 
are physically linked on the genetic map (and are likely inherited together) is 
estimated through the LOD score (the base 10 logarithm of the odds score)113,139. 
The linkage study approach is classically successful in the identification of causal 
variants for conditions with strong heritability, particularly monogenic Mendelian 
disorders139. This study has a very low statistical power to detect genetic variations 
Introduction 
 
	   42	  
with low penetrance and small effect on susceptibility for complex diseases. Hence, 
linkage studies have produced very few reproducible results for CAD140. 
2.2.2 Association studies 
Association studies compare the allelic and genotype frequencies of genetic 
variants among affected and unaffected individuals122. Association studies have more 
statistical power than linkage analysis in detecting genetic contributions to complex 
traits141. The large sample size used in the association studies increase the likelihood 
of identifying common genetic variants with small effects on CAD susceptibility113. 
Association studies can be conducted on genetic variations in a specific gene, 
which is likely involved in the pathogenesis of the considered phenotype (candidate-
gene association study), or on common genetic variants across the whole genome 
(GWAS). 
The major advantage of candidate-gene studies is their avoidance of the multiple-
testing problem that complicates GWAS. However, very few associations identified 
by candidate-gene studies have been consistently replicated for CAD142. Actually, the 
reproducibility of candidate-gene association studies is affected by many factors, such 
as different patterns of SNP in different populations, excessive false-positive rate, 
confounding genetic/environmental factors, and the phenotypic heterogeneity of 
CAD. Meta-analyses have been performed to improve the statistical significance of 
candidate-gene association studies, but are limited by differences in study designs and 
phenotype definitions across studies113. 
ApoE genetic variants have been successfully correlated to CAD susceptibility 
through the candidate-gene association study approach143. 
Limitations of candidate-gene association studies and advances in bioinformatics 
and high-throughput genomic technology have facilitated the transition from 
candidate-gene strategies to GWAS to search for susceptibility genes for common 
CAD. 
The GWA approach is similar to that of candidate-gene association studies in that 
it examines large numbers of unrelated individuals. However, this approach involves 
the genotyping of an unbiased set of hundreds of thousands of markers spanning 
across the whole genome. As the genome-wide approach does not depend on any 
prior assumptions, it has a much greater ability to detect novel susceptibility variants 
that may lead to an improved understanding of disease pathobiology. In addition, 
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large-scale GWAS have greater power than linkage studies to identify genetic variants 
with small effects on CAD susceptibility119,138. Large sample sizes are required to 
detect genes with statistically significant associations that contribute with a small 
effect144. 
To date, the strongest and most consistent association between a genetic locus 
and CAD identified by the GWA approach is on chromosome 9 (chr9p21), reported in 
2007145-148. The variant within the chromosome 9p21 locus that confers CAD risk is 
extremely common, with 75% of the Caucasian population carrying at least 1 allele149. 
The AMI risk conferred by this 9p21 variant is independent of established 
cardiovascular risk factors, but its effect is small (each risk allele increases the 
probability of AMI by 10% to 30% per allele)150. The risk may be different for 
different ethnic groups: actually, the 9p21 locus is a common risk factor for East 
Asians, but not for African-Americans145. Interestingly, there is no evidence that this 
susceptibility locus influences intermediate phenotypes such as established risk 
factors for CAD, suggesting that it may contribute to CAD through novel 
mechanisms149. 9p21 is a region without a known protein-encoding gene150, but 
contains a large antisense noncoding RNA gene (ANRIL) that affects the regulation 
of other genes151. 
2.3 Inflammation in atherosclerosis 
Research has shown that inflammation plays a key role in CAD and other 
manifestations of atherosclerosis. Immune cells dominate early atherosclerotic 
lesions, their effector molecules accelerate progression of the lesions and activation of 
inflammation can elicit acute coronary syndromes. Atherosclerosis, a slowly 
progressing chronic disorder of large and medium-sized arteries, is an inflammatory 
disease in which immune mechanisms interact with risk factors to initiate, propagate, 
and activate lesions in the arterial tree133,138. 
Our views of the pathophysiology of atherosclerosis have evolved substantively 
over the past century. The link between lipids and atherosclerosis dominated our 
thinking until the 1970s, based on strong experimental and clinical relationships 
between hypercholesterolaemia and atheroma152. The emerging knowledge of 
vascular biology led to a focus on growth factors and proliferation of smooth muscle 
cells in the 1970s and 1980s153. Hence, for many years it was believed that 
atherosclerosis was merely passive accumulation of cholesterol in the vessel wall. 
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Today, the picture is much more complex, with atherosclerosis being thought of as a 
chronic inflammatory disease involving innate and adaptive immune mechanisms134. 
 Figure 2.6 | Schematic of the life history of an atheroma. The normal human coronary artery 
has a typical trilaminar structure. The endothelial cells in contact with the blood in the arterial lumen 
rest upon a basement membrane. The intimal layer in adult humans generally contains a smattering of 
smooth muscle cells scattered within the intimal extracellular matrix. The internal elastic lamina forms 
the barrier between the tunica intima and the underlying tunica media. The media consists of multiple 
layers of smooth muscle cells, much more tightly packed than in the diffusely thickened intima, and 
embedded in a matrix rich in elastin as well as collagen. In early atherogenesis, recruitment of 
inflammatory cells and the accumulation of lipids leads to formation of a lipid-rich core, as the artery 
enlarges in an outward, ablumenal direction to accommodate the expansion of the intima. If 
inflammatory conditions prevail and risk factors such as dyslipidaemia persist, the lipid core can grow, 
and proteinases secreted by the activated leukocytes can degrade the extracellular matrix, while pro-
inflammatory cytokines such as interferon-γ (IFN-γ) can limit the synthesis of new collagen. These 
changes can thin the fibrous cap and render it friable and susceptible to rupture. When the plaque 
ruptures, blood coming in contact with the tissue factor in the plaque coagulates. Platelets activated by 
thrombin generated from the coagulation cascade and by contact with the intimal compartment 
instigate thrombus formation. If the thrombus occludes the vessel persistently, an acute myocardial 
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infarction can result (the dusky blue area in the anterior wall of the left ventricle, lower right). The 
thrombus may eventually resorb as a result of endogenous or therapeutic thrombolysis. However, a 
wound healing response triggered by thrombin generated during blood coagulation can stimulate 
smooth muscle proliferation. Platelet-derived growth factor (PDGF) released from activated platelets 
stimulates smooth muscle cell migration. Transforming growth factor-β (TFG-β), also released from 
activated platelets, stimulates interstitial collagen production. This increased migration, proliferation 
and extracellular matrix synthesis by smooth muscle cells thickens the fibrous cap and causes further 
expansion of the intima, often now in an inward direction, yielding constriction of the lumen. Stenotic 
lesions produced by the lumenal encroachment of the fibrosed plaque may restrict flow, particularly 
under situations of increased cardiac demand, leading to ischaemia, commonly provoking symptoms 
such as angina pectoris. Advanced stenotic plaques, being more fibrous, may prove less susceptible to 
rupture and renewed thrombosis. Lipid lowering can reduce lipid content and calm the intimal 
inflammatory response, yielding a more ‘stable’ plaque with a thick fibrous cap and a preserved lumen. 
Adapted from Libby et al.153. 
After the loss of the normal barrier function of the endothelium, the 
atherosclerotic plaque is characterized by an accumulation of lipids in the artery wall, 
together with infiltration of leukocytes, such as macrophages, T cells and mast cells, 
and the formation by vascular smooth muscle cells of a fibrous cap composed mostly 
of collagen. Early lesions called ‘fatty streaks’ consist of subendothelial depositions 
of lipids, macrophage foam cells loaded with cholesterol and T cells. Over time, a 
more complex lesion develops, with apoptotic as well as necrotic cells, cell debris and 
cholesterol crystals forming a necrotic core in the lesion. This structure is covered by 
a fibrous cap of variable thickness and its ‘shoulder’ regions are infiltrated by 
activated T cells, macrophages and mast cells, which produce proinflammatory 
mediators and enzymes154. 
Plaques can remain silent or growth causing stenosis (narrowing of the lumen), 
hence contributing to ischemia in the surrounding tissue and to angina. Thrombosis is 
triggered at the surface of the plaque. Myocardial infarction occurs when the 
atheromatous process prevents blood flow through the coronary artery. It was 
previously thought that progressive luminal narrowing from continued growth of 
smooth muscle cells in the plaque was the main cause of infarction. Angiographic 
studies have, however, identified culprit lesions that do not cause marked stenosis,155 
and it is now evident that the activation of plaque, rather than stenosis, precipitates 
ischemia and infarction156 (Fig. 2.6). 
There are two major causes of coronary thrombosis: plaque rupture and 
endothelial erosion. Plaque rupture, which is detectable in 60 to 70% of cases157, is 
dangerous because it exposes prothrombotic material from the core of the plaque - 
phospholipids, tissue factor, and platelet-adhesive matrix molecules - to the blood. 
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Ruptures preferentially occur where the fibrous cap is thin and partly destroyed. At 
these sites, activated immune cells are abundant158. They produce numerous 
inflammatory molecules and proteolytic enzymes that can weaken the cap and 
activate cells in the core, transforming the stable plaque into a vulnerable, unstable 
structure that can rupture, induce a thrombus that may either obliterate the lumen 
immediately or detach to become an embolus that can block blood flow distal to its 
point of origin134. 
Superficial erosion, or microscopic areas of desquamation of endothelial cells 
that form the monolayer covering the intima, occurs frequently in both humans and 
animals with experimentally induced atherosclerosis. Such areas of limited 
endothelial desquamation often form the nidus of a platelet thrombus as they uncover 
subendothelial collagen and von Willebrand factor that promote platelet adhesion and 
activation159. Although common and most often asymptomatic, such superficial 
erosion may account for approximately 25% of fatal coronary thrombosis153. 
Commonly used experimental mouse models, such as mice rendered 
hypercholesterolemic by targeted deletion of genes encoding molecules involved in 
cholesterol metabolism (such as apolipoprotein E, ApoE–/– mice) or the receptor for 
low-density lipoprotein (LDL; Ldlr–/– mice), are very useful for delineating the 
mechanisms of disease initiation and early growth. However, they are not particularly 
helpful in studies of plaque rupture and thrombosis, which are still based mainly on 
histopathological and clinical studies. The field clearly needs reliable, quantitative 
models for this phase of the disease134. 
2.3.1 Inflammation in initiation of the atherosclerotic process 
Studies in animals and humans have shown that hypercholesterolemia causes 
focal activation of endothelium in large and medium-sized arteries. The infiltration 
and retention of LDL in the arterial intima initiate an inflammatory response in the 
artery wall160,161. Modification of LDL, through oxidation or enzymatic attack in the 
intima, leads to the release of phospholipids that can activate endothelial cells161, 
preferentially at sites of hemodynamic strain162. Patterns of hemodynamic flow 
typical for atherosclerosis-prone segments (low average shear but high oscillatory 
shear stress) cause increased expression of adhesion molecules and inflammatory 
genes by endothelial cells163. Therefore, hemodynamic strain and accumulation of 
lipids may initiate an inflammatory process in the artery.  
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The platelet is the first blood cell to arrive at the scene of endothelial activation. 
Its glycoproteins Ib and IIb/IIIa engage surface molecules on the endothelial cell, 
which may contribute to endothelial activation. Inhibition of platelet adhesion reduces 
leukocyte infiltration and atherosclerosis in hypercholesterolemic mice164. 
Activated endothelial cells express several types of leukocyte adhesion 
molecules, which cause blood cells rolling along the vascular surface to adhere at the 
site of activation165. Since vascular-cell adhesion molecule 1 (VCAM-1) is typically 
up-regulated in response to hypercholesterolemia, cells carrying counter-receptors for 
VCAM-1 (i.e., monocytes and lymphocytes) preferentially adhere to these sites166. 
The mechanism of VCAM-1 induction early after initiating an atherogenic diet 
probably depends on inflammation instigated by modified lipoprotein particles 
accumulating in the arterial intima in response to the hyperlipidaemia. Constituents of 
modified lipoprotein particles can induce transcriptional activation of the VCAM-1 
gene mediated in part by NF-κB167. Pro-inflammatory cytokines such as IL-1β or 
TNFα induce VCAM-1 expression in endothelial cells by this pathway. Human 
atherosclerotic lesions contain these cytokines. Thus, pro-inflammatory cytokines 
may link hypercholesterolaemia to VCAM-1 expression153. 
In addition to VCAM-1, P- and E-selectin also seem to contribute to leukocyte 
recruitment in atherosclerosis-susceptible mice86,168. 
2.3.2 Inflammation in atheroma progression and complication 
Morphologic studies have established that, once adherent to the endothelial cell, 
leukocytes enter the intima by diapedesis between endothelial cells at their junctions. 
Investigators have defined families of chemoattractant cytokines (chemokines) 
capable of recruiting leukocytes into the arterial intima. For example, monocyte 
chemoattractant protein-1 (CCL2/MCP-1), overexpressed in human and experimental 
atheroma, can recruit the mononuclear phagocytes that characteristically accumulate 
in the nascent atheroma. Recent work using compound mutant mice lacking MCP-1 
or its receptor CCR2, and susceptible to atherosclerosis (ApoE–/– or Ldlr–/– mice), has 
shown striking decreases in mononuclear phagocyte accumulation and local lipid 
levels169,170. IL-8 may have a similar role in leukocyte chemotaxis during 
atherogenesis171. 
Once resident in the arterial intima, monocytes acquire the morphological 
characteristics of macrophages, undergoing a series of changes that lead ultimately to 
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foam cell formation. Monocytes increase expression of scavenger receptors from 
modified lipoproteins such as the scavenger receptor A (SRA) and CD36, and then 
internalize modified lipoproteins, such that cholesteryl esters accumulate in 
cytoplasmic droplets. These lipid-laden macrophages, known as foam cells, 
characterize the early atherosclerotic lesion. Macrophages within atheroma also 
secrete a number of growth factors and cytokines involved in lesion progression and 
complication (see below). In addition, macrophages replicate within the intima. 
Years ago macrophage colony-stimulating factor (M-CSF) has been identified as 
a candidate activator of several of the steps that stimulate transition of the monocyte 
to the lipid-laden macrophage. M-CSF augments SRA expression, increases 
production of cytokines and growth factors by these cells, and also serves as a 
survival and comitogenic stimulus. Both experimental and human atherosclerotic 
plaques overexpress M-CSF172,173. 
Granulocyte–macrophage colony-stimulating factor (GM-CSF) may also promote 
inflammation in the atheroma. GM-CSF aids the survival of a population of 
mononuclear phagocytes that contain myeloperoxidase, an enzyme that gives rise to 
the pro-oxidant hypochlorous acid, a potential source of oxidative stress and 
inflammation in the human plaque174. 
The defence of the normal artery depends on innate immune responses mounted 
by endothelial cells and, after an inflammatory challenge, by macrophages and other 
cells of the immune response that are recruited to the artery wall. Such innate immune 
responses also have a major role in the initiation of atherosclerosis and they involve 
pattern-recognition receptors (PRRs)175. 
Scavenger receptors that internalize modified LDL particles are multifunctional 
PRRs that clear the local environment of cell debris, internalize microbes and assist in 
adhesion and antigen presentation. Scavenger receptors that recognize oxidation-
specific epitopes of oxLDL include SRA-1 and SRA-2, MARCO, CD36, SR-B1, 
LOX-1 and PSOX. Although these receptors undoubtedly serve a major role as 
mediators of intracellular cholesterol accumulation, their importance in 
atherosclerosis remains unclear, and gene-knockout studies of hypercholesterolemic 
mice have provided contradictory results176. 
The endothelium of normal and atherosclerotic arteries expresses a broad 
repertoire of signalling PRRs, including Toll Like Receptors TLR1, TLR2, TLR3, 
TLR4, TLR5, TLR7 and TLR9. Monocyte-derived macrophages recruited to forming 
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lesions also express a broad range of TLRs as well as other signalling PRRs177. 
Knockout studies of hypercholesterolemic mice have demonstrated a major 
proatherosclerotic role for MyD88, a key adaptor protein in the signalling cascades of 
most TLRs178,179. Targeted deletion of the gene encoding TLR4 also results in less 
atherosclerosis, albeit to a smaller extent. Of note, MyD88 also participates in the 
signal-transduction pathway downstream of the receptors for IL-1 and IL-18, two 
proatherosclerotic cytokines180,181. Therefore, part of the diminished disease observed 
in MyD88-deficient mice probably also reflects the loss of signalling by IL-1β and IL-
18134. 
Moreover, oxidized LDL, and components thereof, can ligate particular TLRs 
(like TLR2 and 4)182,183. Further studies will be needed to clarify the role of these 
ligand-receptor interactions134. 
2.3.3 Adaptive immune system in atherosclerosis 
Components of adaptive immunity are present in human lesions throughout the 
course of atherosclerosis, and several studies have indicated an important role for 
antigen-specific adaptive immune responses in the atherogenic process. Studies of 
mouse models of atherosclerosis, such as ApoE–/– or Ldlr–/– mice, in combination with 
mice deficient in both B cells and T cells, have demonstrated a substantial role for the 
adaptive arm of immunity in atherosclerosis184. 
Some experiments have suggested that B cells have a protective role: antibodies 
to oxLDL in particular are atheroprotective. Many experimental studies of rabbits and 
mice in which oxLDL is used for immunization have shown a positive correlation 
between high titers of anti-oxLDL and the degree of protection against 
atherosclerosis185,186. As is often the case, the situation is more complex in humans, 
with various studies showing a positive or negative correlation or no correlation 
between anti-LDL titers and atherosclerosis or its manifestations187-189. Interestingly, 
titers of IgM and IgG antibodies to oxLDL have been found to show differences in 
their associations with CAD, which suggests that their biological roles also differ190. 
A T-cell infiltrate is always present in atherosclerotic lesions. Such infiltrates are 
predominantly CD4+ T cells, which recognize protein antigens presented to them as 
fragments bound to major-histocompatibility-complex (MHC) class II molecules. 
CD4+ T cells reactive to the disease-related antigens oxLDL, heat-shock protein 60, 
and Chlamydia proteins have been cloned from human lesions191-193. In fact, several 
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studies have linked infections to atherosclerosis and CAD. In particular, Chlamydia 
pneumoniae and cytomegalovirus may contribute to CAD, but it is unlikely that a 
single microbe causes atherosclerosis. Instead, the total burden of infection at various 
sites may affect the progression of atherosclerosis and elicit clinical manifestations194. 
A minor T-cell subpopulation, natural killer T cells, is prevalent in early lesions. 
Natural killer T cells recognize lipid antigens, and their activation increases 
atherosclerosis in ApoE–/– mice195. CD8+ T cells restricted by MHC class I antigens 
are also present in atherosclerotic lesions. These cells typically recognize viral 
antigens, which may be present in the lesions. Activation of CD8+ T cells in ApoE–/– 
mice can cause the death of arterial cells and accelerate atherosclerosis196. 
Atherosclerosis is driven by the T helper type 1 (Th1) response. Interferon-γ, the 
signature Th1 cytokine, is present in the human plaque and has pathogenic effects, 
including less collagen fiber formation, higher expression of MHC class II, enhanced 
protease and chemokine secretion, upregulation of adhesion molecules, induction of 
proinflammatory cytokines, and enhanced activation of macrophages and endothelial 
cells154. Mice deficient in interferon-γ or its receptor have a lower lesion burden, and 
mice that receive interferon-γ have larger lesions than those of control mice197,198. 
Injection of IL-12 also promotes the formation of early lesions199, whereas targeted 
deletion of the gene encoding IL-12 or vaccination against IL-12 inhibits early but not 
late lesion development200,201. Furthermore, mice lacking IL-18, a Th1-promoting 
cytokine, have smaller lesions181, whereas mice treated with IL-18 have more 
atherosclerosis202. 
Collectively these data demonstrate that Th1 cells have a major role in the 
pathogenesis of atherosclerosis. IL-4, the signature cytokine of the Th2 lineage, is not 
frequently observed in human plaques203, and experimental studies examining the 
involvement of Th2 cells are contradictory, with some showing proatherosclerotic 
effects200,204 and others showing protective effects205 or no significant effect206. IL-33, 
a powerful inducer of Th2 responses, results in less atherosclerosis in ApoE–/– 
mice183. On balance, then, the role of Th2 immune responses in atherosclerosis 
remains unclear. 
T-cell cytokines cause the production of large amounts of molecules downstream 
the cytokine cascade. As a result, elevated levels of IL-6 and CRP may be detected in 
the peripheral circulation. In this way, the activation of a limited number of immune 
Introduction 
 
	   51	  
cells can initiate a potent inflammatory cascade, both in the forming lesion and 
systemically133. 
2.3.4 Inflammation and plaque disruption 
Growth factors elaborated by macrophages in the atherosclerotic intima 
supposedly stimulated the replication of smooth muscle cells, which accumulate in the 
plaque and lay down an abundant extracellular matrix134. 
Among the forms of plaque disruption, we best understand fracture of the fibrous 
cap. Interstitial collagen molecules confer most of the tensile strength on the fibrous 
cap, and several tightly regulated processes determine the level of collagen crucial for 
stability of this structure. Certain pro-inflammatory cytokines, such as IFN-γ, can 
inhibit collagen production by smooth muscle cells, the principle source of this 
extracellular matrix macromolecule in the arterial wall. Interstitial collagen fibrils 
usually resist proteolytic degradation, and only a limited number of interstitial 
collagenases can make an initial proteolytic nick in the collagen chains that make up 
the triple helical collagen fibril153. 
Two types of proteases have been implicated as key players in plaque activation: 
matrix metalloproteinases (MMPs) and cysteine proteases207,208. Several members of 
these families of enzymes occur in the plaque and may degrade its matrix. MMP 
activity is controlled at several levels: inflammatory cytokines induce the expression 
of MMP genes, plasmin activates proforms of these enzymes, and inhibitor proteins 
(tissue inhibitor of metalloproteinase) suppress their action. Similarly, cysteine 
proteases are induced by certain cytokines and checked by inhibitors termed 
“cystatins.” Several of these molecules play decisive roles in the formation of 
aneurysms, as shown by experiments in gene-targeted mice. However, mechanistic 
studies in models of atherosclerosis have yielded complex results, with certain MMPs 
reducing rather than increasing the size of the lesions. At the same time, these 
enzymes clearly affect the composition of plaque. Therefore, they may represent 
future therapeutic targets. Study of plaque rupture in animal models should be helpful 
in determining the role of these proteases in the activation of plaque and myocardial 
infarction133. 
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3-microRNAs: new regulators of gene expression 
The recent discovery of microRNAs (miRNAs) has revealed a new level of gene 
expression regulation that affects many biological systems, including the mammalian 
immune system209,210. miRNAs are small, single-stranded non-coding RNAs, many of 
which have been highly conserved throughout evolution. They function by directly 
binding to the 3ʹ untranslated region (3’UTR) of specific target mRNAs, leading to 
the repression of protein expression. So far, ~1500 different miRNAs have been 
identified in the human genome. Each miRNA could have the potential to repress the 
expression of many, perhaps hundreds, of target genes, highlighting the extent of this 
form of regulation in mammals. More than 100 different miRNAs are expressed by 
cells of the immune system; they have the potential to broadly influence the molecular 
pathways that control the development and function of innate and adaptive immune 
responses. The expression of miRNAs is also markedly deregulated in cancers of 
immunological origin, in which they are thought to have tumour suppressive or 
tumour promoting activities depending on the nature of their specific target 
mRNAs211. 
3.1 The case of lin-4 and the microRNA discovery 
The investigation that led to the discovery of microRNAs was conducted by 
Victor Ambros, Rosalind Lee and Rhonda Feinbaum. They found that lin-4, a gene 
known to control the timing of Caenorhabditis elegans larval development, does not 
code for a protein but instead produces a pair of small RNAs212. One RNA is 
approximately 22 nucleotides (nt) in length, and the other is approximately 61 nt-
long; the longer one was predicted to fold into a stem loop proposed to be the 
precursor of the shorter one. The authors then noticed that these lin-4 RNAs had 
antisense complementarity to multiple sites in the 3’UTR of the lin-14 gene212,213. 
This complementarity fell in a region of the 3’UTR previously proposed to mediate 
the repression of lin-14 by the lin-4 gene product214. The scientists demonstrated the 
importance of these complementary sites for regulation of lin-14 by lin-4, showing 
also that this regulation substantially reduces the amount of LIN-14 protein without 
noticeable change in levels of lin-14 mRNA. Together, these discoveries supported a 
model in which the lin-4 RNAs pair to the lin-14 3’UTR to specify translational 
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repression of the lin-14 message as part of the regulatory pathway that triggers the 
transition from cell divisions of the first larval stage to those of the second212,213. 
The shorter lin-4 RNA is now recognized as the founding member of an abundant 
class of tiny regulatory RNAs called microRNAs or miRNAs215-217. 
3.2 The microRNA genes and function 
In C. elegans another gene, let-7, was found to encode for a ~22 nt regulatory 
RNA. The let-7 RNA acts to promote the transition from late-larval to adult cell fates 
in the same way that the lin-4 RNA acts earlier in development to promote the 
progression from the first larval stage to the second218,219. Furthermore, homologs of 
the let-7 gene were soon identified in the human and fly genomes, and let-7 RNA 
itself was detected in human, Drosophila, and eleven other bilateral animals220. 
Because of their common roles in controlling the timing of developmental 
transitions, the lin-4 and let-7 RNAs were dubbed small temporal RNAs (stRNAs), 
with anticipation that additional regulatory RNAs of this type would be discovered220. 
Indeed, less than one year later, three labs cloning small RNAs from flies, worms, and 
human cells reported a total of over one hundred additional genes for tiny noncoding 
RNAs215-217. The RNA products of these genes resembled the lin-4 and let-7 stRNAs 
in that they were ~22 nt endogenously expressed RNAs, potentially processed from 
one arm of a stem loop precursor, and they were generally conserved in evolution. But 
unlike lin-4 and let-7 RNAs, many of the newly identified ~22 nt RNAs were not 
expressed in distinct stages of development and instead were more likely to be 
expressed in particular cell types. Thus the term microRNA was used to refer to the 
stRNAs and all the other tiny RNAs with similar features but unknown functions215-
217. Actually, different miRNA expression profiles can be detected according to the 
development stage, the differentiation stage or the cell type. A distinct pattern of 
miRNA expression provides the opportunity for “micromanaging” the output of the 
transcriptome221. 
Like C. elegans lin-4 and let-7, most miRNA genes come from regions of the 
genome quite distant from previously annotated genes, implying that they derive from 
independent transcription units215-217. About a quarter of the human miRNA genes are 
in the introns of pre-mRNAs. These are preferentially in the same orientation as the 
predicted mRNAs, suggesting that most of these miRNAs are not transcribed from 
their own promoters but are instead processed from the introns. This arrangement 
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provides a convenient mechanism for the coordinated expression of a miRNA and a 
protein. Regulatory scenarios are easy to imagine in which such coordinate expression 
could be useful, which would explain the conserved relationships between miRNAs 
and host mRNAs221. 
miRNA genes can be clustered in the genome with an arrangement and an 
expression pattern implying transcription as a multi-cistronic primary transcript215,216 
or isolated, like the majority of worm and human miRNA genes are222,223. In contrast, 
in Drosophila over half of the known miRNAs are clustered224. The miRNAs within a 
genomic cluster are often, though not always, related to each other; and related 
miRNAs are sometimes but not always clustered215,216. This example illustrates the 
possibility that even in cases where clustered genes have no apparent sequence 
homology, they may share functional relationships221. 
3.3 The microRNA biogenesis and mechanism of action 
Our knowledge of miRNA biogenesis and mechanisms of target mRNA 
regulation by miRNAs is expanding in parallel with our understanding of their 
physiological roles. The processes of miRNA biogenesis and target mRNA repression 
(Fig. 3.1) have been intensively studied in recent years225. miRNAs are encoded by 
genomic DNA and are most commonly transcribed by RNA polymerase II. miRNAs 
are processed from their primary transcripts (known as pri-miRNAs) by the 
microprocessor complex, which consists of the RNase III type endonuclease Drosha 
(also known as ribonuclease 3) and its partner DiGeorge syndrome critical region 
gene 8 (DGCR8), and recent data suggest that this occurs co-transcriptionally226. The 
precursor-microRNA (pre-miRNA) generated by the microprocessor complex is a 70 
nt stem loop that is then actively exported from the nucleus to the cytoplasm by 
exportin 5. On reaching the cytoplasm, further processing of the pre-miRNA is carried 
out by Dicer, another RNase III type endonuclease, and TAR RNA-binding protein 
(TRBP, also known as TARBP2) resulting in the formation of a miRNA duplex 20 nt-
long. The duplex is unwound, and one strand, the guide strand, is packaged into the 
RNA-induced silencing complex (RISC), which comprises Argonaute and other 
proteins. The miRNA then guides the RISC to its target 3ʹ UTRs, leading to inhibition 
of translation and/or a decrease in mRNA stability as a result of accelerated 
uncapping and deadenylation227,228. The deadenylation process, through which the 
polyA tail is removed from the mRNA, is reached by fostering the activity of 
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deadenylases (such as CCR4-NOT) and is followed by mRNA instability and 
degradation. The mRNA translation is blocked at the initiation step or at the 
elongation step by inhibiting the eukaryotic initiation factor 4E (EIF4E)229. 
Figure 3.1 | RNA biogenesis and mechanism of action. Adapted from Inui et al.229. 
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The mature miRNA has only a partial complementary with its target. In 
particular, the perfect base pairing between the seed sequence of the miRNA (from 
the second to the eighth nucleotide) and the seed match sequence in the mRNA 
3’UTR is crucial229. The lack of perfect complementarity prevents the target from 
being sliced by the Argonaute proteins that are responsible for the “slicer” activity of 
the RISC. In addition, some Argonaute proteins in humans lack the catalytic residues 
needed for the slicer activity230. Actually, of the four human Argonaute proteins 
(AGO1, AGO2, AGO3 and AGO4), only AGO2 has demonstrable slicer 
activity231,232. There is evidence that the miRNA-silenced mRNA is directed to 
processing bodies (P-bodies), in which the targeted transcript is released from its 
inhibition or actively degraded233. 
3.4 The prediction of miRNA targets and of mRNA-targeting 
miRNAs 
Currently, the official miRNA database miRBase lists 1527 human miRNAs 
(http://www.mirbase.org; Release 18)234. 
Computational methods for miRNA target prediction are very important, 
considering the long experimental procedures needed for verifying the direct 
interaction between a microRNA and its target. The task is complicated by the fact 
that, as mentioned above, the complementarity between miRNA:mRNA is far from 
being perfect. Consequently, a simple search for sequence complementarity is 
expected to produce many false-positive hits. Moreover, the repression of some of the 
several miRNA-targets is stronger than for others. Ideally, one should therefore 
predict not just targets, but also the expected degree of translational suppression235. 
The crucial feature for target recognition is the miRNA:mRNA pairing in at least 
one region. The microRNA region involved in this Watson-Crick pairing (the “seed”) 
is located at the 5’ end of the miRNA sequence (from position 1-2 to position 7-8). 
The corresponding site in the messenger is called “seed site” or “seed region”. There 
are four seed types: 8mer, 7mer-m8, 7mer-A1 and 6mer, depending on the 
combination of the nucleotide of position 1 and pairing at position 8 (Fig. 3.2). The 
6mer is the perfect 6 nt match to the miRNA seed (miRNA nucleotides 2–7). The best 
7mer site, referred to as the 7mer-m8 site, contains the seed match augmented by a 
match to miRNA nucleotide 8. Also effective is another 7mer, the 7mer-A1 site, 
which contains the seed match augmented by an A at target position 1. The 8mer site 
Introduction 
 
	   57	  
comprises the seed match flanked by both the match at position 8 and the A at 
position 1236. In addition, Watson–Crick pairing in the 3’ of miRNA is known to 
enhance the site recognition efficacy in miRNA targets that have seed pairing236. 
Figure 3.2 | Types of miRNA target sites. Adapted from Grimson et al.241. 
Although functional miRNA sites are preferentially located in the 3’UTR, seed 
sites in the coding sequence (CDS) and in the 5’UTR regions can also give 
downregulation237,238. Why does RISC then appear to prefer the 3’UTR? The most 
probable explanation is that RISC competes with other protein complexes, such as 
ribosomes in CDS and translation initiation complexes in 5’UTR. The 3’UTR might 
simply be more accessible for long-term binding than the two other mRNA regions221. 
Most miRNA target prediction studies only focus on the 3’UTR. Target genes tend to 
have longer 3’UTR, whereas ubiquitously expressed genes, such as house-keeping 
genes, have shorter 3’UTR – potentially to avoid being regulated by miRNAs239. 
Target sites are not evenly distributed within 3’UTR, but are located near both ends 
when the length of 3’UTR is ≥2000 nt. For shorter 3’UTRs, sites tend to be near the 
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stop codon240. Sites are not located too close to the stop codon, however, but 15–20 nt 
away from it241. 
Additionally, strong miRNA targets tend to have multiple target sites instead of 
one single site242. Although the general effect of multiple sites appears to be additive, 
miRNA targeting can also be synergistic. Two target sites within optimal distance 
enhance target site efficacy: the preferable optimal length is between 17 and 35 nt, but 
the length between 14 and 46 nt also enhances the efficacy. This co-operability is 
functional between the same miRNAs as well as two different miRNAs. Multiple sites 
involving more than two sites can also contribute to the enhancement242. The exact 
mechanism underlying the synergism remains unknown. Multiple RISC complexes 
bound at closely spaced target sites might cooperatively stabilize each other at the 
sites or possibly accelerate the regulatory process243. Considering the number of 
putative miRNA sites per mRNA can therefore significantly enhance target 
prediction. 
miRNA families are comprised of miRNAs that have the same seed site, and are 
well conserved among related species. In addition, miRNA families have targets that 
are conserved among related species244. There are also species-specific miRNAs and 
targets, and one study showed that about 30% of the experimentally validated target 
genes might not be well conserved245. 
The mRNA secondary structure is very important for miRNA targeting. An 
effective miRNA:mRNA interaction needs an open structure on the target site to 
begin the hybridization reaction and the mRNA must not to be involved in any 
intramolecular base pairing246. The total free-energy change, ΔΔG, of the binding 
process is therefore determined by the difference between the energy expended on 
opening target-site structure and that gained by forming the duplex. ΔΔG correlates 
well with the experimentally measured degree of mRNA suppression, suggesting that 
the dominant mechanism of miRNA target recognition is in fact simple equilibrium 
thermodynamics, and that ΔΔG determines the equilibrium constant of the binding 
reaction235. 
One miRNA can potentially regulate many genes; therefore, expression profiles 
of mRNAs might vary substantially depending on the miRNA expression levels. 
Many miRNAs are also expressed differently in different tissues. Consequently, it is 
essential that the miRNA and its putative target are co-expressed in the same cell 
type. Moreover, if the expression levels of the miRNA and the mRNA are negatively 
Introduction 
 
	   59	  
correlated probably they interact each other. Filtering putative targets based on 
expression profile correlations is an effective approach to reduce the false-positive 
rate. Although the majority of miRNA targets appear to be regulated both at the 
mRNA and protein level, some targets only show an effect at the protein level, 
however243,247. 
Among the bioinformatic tools for prediction of miRNA targets and mRNA-
targeting miRNAs in mammalian/vertebrates, TargetScan and Miranda are executable 
online tools. TargetScan often shows best performance in comparison243. Actually, it 
considers only stringent seed pairing, site number, the conservation of miRNAs and of 
the seed sites and site context (which includes factors that influence site accessibility). 
Miranda considers, on the other hand, a moderately stringent seed pairing and site 
number248. 
3.5 microRNAs in immunity and inflammation 
3.5.1 The physiological role of microRNAs in the immune system 
Haematopoietic stem cells (HSCs) reside mainly in the bone marrow and give 
rise to all blood cell lineages, including cells that constitute the immune system249. 
HSCs must maintain a precise balance between self-renewal and differentiation into 
multipotent progenitors, which subsequently give rise to both the lymphoid and 
myeloid branches of the haematopoietic system. Although miRNAs have been studied 
in other stem cell types, such as embryonic stem cells, there are currently limited data 
on the role of miRNAs in HSCs250. Several groups have carried out global miRNA 
expression profiling of human CD34+ stem and progenitor cells and have identified 
certain miRNAs expressed by this cell population251,252. Mice deficient in ARS2, 
which contributes to pri-miRNA processing, have bone marrow failure possibly 
owing to defective HSC function253. These studies provide initial evidence that the 
miRNA pathway is important in HSC function210. 
Cells of the innate immune system, such as granulocytes, monocytes (which 
differentiate into myeloid-derived DCs or macrophages) and natural killer (NK) cells, 
provide an important first line of defence against infection. Emerging data have 
identified an important contribution of miRNAs to the development and function of 
innate immune cells. Similar to the development of innate immune cells, the 
development of T cells in the thymus and their activation in the periphery are also 
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controlled by complex protein signalling networks that are subject to regulation by 
miRNAs. Expression profiling of T cells has identified a broad range of expressed 
miRNA species and found that the expression patterns vary between T cell subsets 
and stages of development. Conditional deletion of Dicer in T lymphocytes results in 
many fewer T cells in the thymus and periphery254. The generation of B cells that 
express high-affinity antigen receptors involves two main stages: antigen-independent 
development in the bone marrow and antigen-dependent selection in the secondary 
lymphoid organs; both of which are associated with dynamic regulation by miRNAs. 
Dicer deficiency in B lymphocytes has been shown to diminish B cell survival and the 
antibody repertoire255(see ref. O’Connell et al.210). 
3.5.2 The microRNA control of signalling cascades (e.g. the TLR signalling) 
Uncovering the function of individual miRNAs is challenging. First, miRNAs are 
frequently present as families of redundant genes, which complicates genetic 
dissections. Second, each miRNA has numerous putative targets that have disparate 
functions, with no means to decide a priori which one is most meaningful and thus 
worthy of experimental validation. Third, the degree of target downregulation 
imposed by miRNAs often tends to be quantitatively modest: measured at the protein 
level, even an overexpressed miRNA typically down-regulates most of its endogenous 
targets by less than 50%247. Therefore, most proteins should remain effective over this 
degree of inhibition, an argument supported by the paucity of haploinsufficient 
phenotypes that have been described so far. Conversely, few genes are known to have 
phenotypes when duplicated, perhaps mimicking the situation when miRNA-mediated 
regulation of a target is lost. These considerations suggest that even though most 
genes are predicted to be miRNA targets, only a fraction of these interactions will 
prove instrumental for overt biological responses and phenotypes248. Remarkably, 
however, inhibition of miRNA biogenesis (for example, through the ablation of 
Dicer) clearly reveals that miRNAs are essential for a wide array of biological 
processes, including control of proliferative homeostasis, differentiation or embryonic 
stemness256. 
Signal transduction pathways are prime candidates for miRNA-mediated 
regulation in animal cells. Signalling complexes are indeed highly dynamic and 
ephemeral molecular ensembles, which translate into well-established dose-dependent 
responses. As such, they are the ideal targets for the degree of quantitative 
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fluctuations imposed by miRNAs. This might enable the multi-gene regulatory 
capacity of miRNAs to remodel the signalling landscape, facilitating or opposing the 
transmission of information to downstream effectors in an effective and timely 
manner257. miRNAs targets are either positive or negative modulators of key 
signalling pathways229. 
MicroRNAs, emerged as immunomodulators, are important controllers of Toll-
like receptor (TLR) signalling. It is well established that TLRs have important roles in 
detecting pathogens and in initiating inflammatory responses that subsequently prime 
specific adaptive immune responses during infection258. It has also been recognized 
that deregulation of this process is a hallmark of inflammatory and autoimmune 
diseases259. It is therefore important that TLR signalling pathways are tightly 
regulated. Actually, the signalling molecules of each TLR signalling pathway are 
regulated by numerous mechanisms, including physical interactions, conformational 
changes, phosphorylation, ubiquitylation and proteasome-mediated degradation260. 
The miRNA-mediated control of the expression of these signalling molecules — 
through either mRNA decay or translational inhibition — might not be as rapid as 
control through proteasomal degradation; however, this might be an advantage during 
infection, as miRNA-mediated control of mRNA levels allows for a strong initial 
immune response that is gradually dampened down261. 
The end result of the TLR signalling pathways is the activation of pro-
inflammatory transcription factors that enhance the transcription of RNA polymerase 
II-sensitive genes such as those encoding cytokines, chemokines and antimicrobial 
enzymes. Because miRNAs are also transcribed by RNA polymerase II, it stands to 
reason that miRNAs themselves are targets of TLR signalling pathways261. 
Multiple miRNAs are induced in innate immune cells, with a consensus emerging 
that miR-155, miR-146 and miR-21 are particularly ubiquitous. There is also evidence 
that the expression of certain miRNAs can decrease following TLR activation. Similar 
to other TLR-responsive genes, miRNAs can be classified as early or late response 
genes: some miRNAs (e.g. miR-155) are highly induced 2 hours after treatment, 
whereas other miRNAs (e.g. miR-21) are induced at later times. The expression of 
most TLR-responsive miRNAs described so far depends on NF-κB activity. It is also 
important that the induction of TLR-responsive miRNAs is regulated and mechanisms 
are now being discovered that negatively regulate miRNA induction by TLR 
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signalling; for example, miR-155 in particular is subject to negative regulation by 
interleukin-10 (IL-10)262. 
Table 3.1 | Verified miRNA-targets belonging to the TLR signalling. Adapted from O’Neill et 
al.261 (for references see O’Neill et al.261) 
Target mRNA miRNA(s) 
Receptors   
TLR4 miR-223, let-7i, let-7e 
TLR3  miR-223 
TLR2  miR-105 
Signalling molecules   
MYD88 miR-155 
MAL miR-145 
IRAK1 miR-146 
IRAK2 miR-146 
TRAF6 miR-146 
BTK miR-348 
TAB2 miR-155 
IKKα miR-223 
IKKβ miR-199 
IKKε miR-155 
Transcription factors   
NF-κB1 miR-9 
FOXP3 miR-155 
C/EBPβ miR-155 
PPARγ miR-27b 
p300 miR-132 
Cytokines   
IL-6 let-7 
TNF miR-16, miR-125b, miR-155, miR-221, miR-579, miR-369-3 
IL-10 miR-106, miR-466l 
IL-12p35 miR-21 
Regulators   
ACHE miR-132 
PDCD4 miR-21 
SHIP1 miR-155 
SOCS1 miR-155 
 
Very recently, the ceRNA (competitive endogenous RNA) hypothesis has been 
proposed by Pandolfi et al. They hypothesize that all types of RNA transcripts (from 
protein coding-gene and pseudogenes to long noncoding RNAs, lncRNAs) can 
crosstalk through the micro-RNA binding elements (MREs), forming a large-scale 
regulatory network across the transcriptome that is governed by microRNA 
competition. According to the ceRNA hypothesis, pseudogenes and lncRNAs can 
compete with protein-coding genes for the same pool of microRNAs through sets of 
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conserved MREs. With this logic, mRNAs, usually viewed as passive targets of 
micro-RNAs mediated repression, possess the noncoding function of regulating the 
activity of microRNAs263. 
In Table 3.1, the verified targets of miRNAs in TLR signalling are summarized. 
The targets belong to all the molecule categories involved in the signalling cascade: 
receptors, signalling proteins, transcription factors, cytokines and regulators261. 
The molecular targets of miR-146a are IL-1R-associated kinase 1 (IRAK1) and 
TNFR-associated factor 6 (TRAF6)264. These proteins are important components of 
the myeloid differentiation primary-response protein 88 (MyD88)-dependent pathway 
for NF-κB activation downstream of TLR2, TLR4, TLR5, TLR7–TLR8 and TLR9, 
which are the same TLRs that induce expression of miR-146 in the THP-1 cell line. It 
was postulated that miR-146a could negatively regulate the MyD88–NF-κB signalling 
pathway after bacterial infection264. Recently, IRAK2, a kinase that is required for the 
persistence of NF-κB activation, has also been shown to be targeted by miR-146a265. 
Since a too strong or too prolonged innate immune response can have detrimental 
effects, resulting in acute and chronic inflammatory disorders, the immune system 
cells have to stringently employ a multilayered structure to control the immune 
response266. miR-146a belongs to this mechanism of control and, actually, it was the 
first identified immune system regulator in a systematic effort to find miRNAs that 
influence the mammalian response to microbial infection264. 
Not only in THP-1 cells, but also in human primary DCs, miR-146a production 
increases in response to LPS267, whereas in B cells with latent infection with Epstein-
Barr virus, miR-146a expression increases as a result of signalling of the virus-
encoded latent membrane protein 1 (LMP1), which acts as a constitutively active 
homolog of the TNF receptor268. Many expression-profiling studies have 
demonstrated distinct patterns of miR-146 expression in various hematopoietic 
lineages, which suggests its involvement in the maintenance of lineage identity in 
lymphocyte subsets. For example, miR-146 abundance is higher in T helper type 1 
cells, but lower in T helper type 2 cells relative to that in mature naive T cells269. In 
addition, miR-146 is among the most highly expressed miRNAs in regulatory T cells, 
and overall, the miRNA expression pattern of the regulatory T cell lineage resembles 
the profile of activated rather than naive T cells270. 
The miR-146a miRNA has been illustrated as one of the key molecules not only 
of the inflammatory response but also of oncogenesis271. The high expression of miR-
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146a has been shown to be up-regulated in many inflammatory diseases such as 
osteoarthritis and rheumatoid arthritis (RA), the latter involving up-regulation 
following stimulation with inflammatory cytokines such as TNFα and IL1-β. 
Interestingly, a polymorphism in the 3’UTR of the mRNA encoding the miR-146a 
target IRAK1 is associated with a susceptibility to RA272 and psoriatic arthritis273. 
An additional highly interesting paper274 implicated loss of miRNA function with 
susceptibility to disease. miR-146a, along with miR-145, were pinpointed as key 
mediators of 5q syndrome, a subtype of myelodysplastic syndrome, one of the most 
common haematopoetic malignancies which progresses to acute myeloid leukaemia. 
5q syndrome is defined by an isolated interstitial deletion of chromosome 5q that 
leads to the loss of the genes encoding miR-146a and miR-145. The authors proposed 
a model in which deletion of 5q results in haploinsufficiency of miR-145 and/or miR-
146a. The subsequent increased expression of the miRNA target genes TIRAP and 
TRAF6 leads to inappropriate activation of innate immune signalling. This activation 
of the TRAF6-mediated signalling pathway leads to cell abnormalities and to the 
tendency of developing marrow failure and acute leukaemia. 
Regarding miR-155 that is processed from a primary transcript, called ‘BIC’, 
there is mounting evidence that it can negatively regulate TLR signalling pathways by 
targeting key signalling proteins. Inhibition of miR-155 in DCs resulted in 
upregulated expression of components of the p38 mitogen-activated protein kinase 
(MAPK) pathway275. TAK1-binding protein 2 (TAB2), a signalling molecule 
downstream of TRAF6 that activates MAPK kinases, was confirmed as a direct target 
of miR-155275. MyD88 has also been identified as a target of miR-155 in studies of 
miR-155 induction by Helicobacter pylori276. Furthermore, MyD88 is a target of miR-
155 in foam cells, which induce the expression of miR-155 when loaded with 
oxidized low-density lipoprotein277. Analysis of both miR-155 and its Kaposi’s 
sarcoma-associated herpesvirus (KSHV) homologue has identified IKKε as a 
potential target, which supports the notion that miR-155 can negatively regulate 
innate immune signalling278,279. The transcriptional co-repressor CCAAT/enhancer-
binding protein-β (C/EBPβ) has been identified as another target of miR-155280. 
All together these results highlighted a negative effect on inflammation exerted 
by miR-155, but, in addition, miR-155 targets two negative regulators of cytokine-
mediated and TLR signalling pathways: the suppressor of cytokine signalling 1 
(SOCS1)281 and SHIP1282. These data elucidate a role of miR-155 as a positive 
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regulator of immunity266, like the studies on miR-155 knockout mice suggested. 
Actually, miR-155 knockout mice, the first immunologically significant miRNA-
deficient animals generated, are immunodeficient, producing lower levels of antibody 
with impaired B-cell function and skewed Th2 responses. They also develop changes 
to lung tissue, with scarring that is similar to some human systemic autoimmune 
disorders283,284. Both the positive and negative aspects of these control mechanisms 
implicate miR-155 as a highly interesting and significant player in downstream 
inflammatory pathways, and further research in this area will elucidate its main role in 
the immune response266. 
In monocytes, macrophages and myeloid DCs, miR-155 increases substantially 
after exposure to a variety of inflammatory stimuli264,267. Direct recognition of 
microbial products by TLRs, particularly pathogen-associated molecular motifs 
derived from bacteria or viruses, leads to miR-155 upregulation. Furthermore, a 
plethora of immunoregulatory cytokines, such as TNF and interferons, also induce 
miR-155 upregulation in macrophages. Because miR-155 induction involves both the 
transcription factor NF-κB and the kinase Jnk it fits the profile of a typical immune-
response molecule285. The function of miR-155 in macrophages remains an open 
issue. Further elucidation of miR-155 targets should show whether it is a positive or 
negative regulator of the macrophage inflammatory response or whether it has a more 
specialized task. For example, miR-155-deficient myeloid DCs have an impaired 
ability to trigger T cell activation after antigen presentation, which indicates its 
involvement in bridging innate and adaptive immunity283. 
Moreover, miR-155 was the first oncogenic miRNA (“onco-miR”) to be 
discovered and, now, it is at the centre of much research as both a biomarker and 
promoter of several types of B-cell lymphoma, in particular Hodgkin’s lymphoma and 
diffuse large B-cell lymphoma, since its expression elevated in these diseases266. 
Finally, in KSHV-infected lymphatic endothelial cells, miR-132 was shown to 
directly target the transcriptional co-activator p300, which is often associated with 
cAMP-responsive element-binding protein (cREB) and is required for the induction of 
antiviral genes286. The identification of another target of miR-132, such as the 
acetylcholinesterase (ACHE), a key regulator of TLR signalling, has provided links 
between TLRs and neuroinflammation. ACHE hydrolyses acetylcholine (an important 
component of the cholinergic anti-inflammatory pathway that is released by efferent 
vagus nerve fibres) and acetylcholine can block NF-κB nuclear translocation in 
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macrophages and thus attenuate TLR-induced innate immune responses. So, an 
increase in miR-132 levels in response to TLR stimulation will result in the repression 
of ACHE and increased acetylcholine-mediated negative regulation of TLR-induced 
signals. Indeed, LPS-treated macrophages from mice in which the 3ʹUTR of Ache 
mRNA has been deleted and therefore cannot bind miR-132 overproduce IL-6, IL-12 
and TNF287. 
More recently, the TLR- responsive miRNA miR-9 was shown to directly target 
NF-κB1 mRNA. NF-κB1 is cleaved to form the NF-κB p50 subunit, which has an 
important role in transactivation of the NF-κB p65 subunit. Therefore, the finding that 
miR-9 can target the NF-κB1 gene identifies a key control point for TLR signalling288.  
In conclusion, microRNAs function as efficient fine-tuners of protein expression, 
rather than as “on-off” switches, and they represent a mechanism to tone down the 
inflammatory response, which left unchecked, can have catastrophic effects209. 
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Aim of the thesis 
Of the estimated 30˙000 genes in the human genome, only a small fraction is 
activated in each cell type according to the particular stage of cell differentiation, the 
cell function and the environment. Gene expression is a highly specific process that 
allows the cell to function. Indeed, a change in the DNA code or a variation in any of 
the intermediate steps of gene expression process could give rise to a biological effect 
and/or a clinical phenotype. Single nucleotide polymorphisms (SNPs) and 
microRNAs represent two ways in which gene expression can be modified/regulated 
at two different levels. 
The long pentraxin PTX3 is involved in angiogenesis, tissue remodelling and 
female fertility and it is an important effector and modulator of innate resistance and 
inflammation. PTX3, like all the members of pentraxin superfamily, is conserved in 
evolution from arachnids and insects to humans. This conservation is a demonstration 
of its crucial role in complex organisms. Indeed, a correct regulation of PTX3 
expression is critical. 
The purpose of this thesis was the investigation of two potential levels of PTX3 
regulation: PTX3 gene SNPs and PTX3-targeting microRNAs. SNPs are permanent 
transmissible variations in DNA sequence occurring in more than 1% of a population. 
SNPs can be associated to some clinical conditions, for example modifying the 
susceptibility to common complex diseases, like coronary artery disease. microRNAs 
inhibit the translation of specific targets at the post-transcriptional level and they 
could therefore be as important as transcription factors in controlling the protein 
content of a cell. 
Hence, aims of this thesis were: 
Aim 1 – to address the role of PTX3 single nucleotide polymorphisms in 
modulating the susceptibility to acute myocardial infarction and PTX3 plasma levels; 
Aim 2 – to evaluate the microRNA-mediated regulation of PTX3 expression. 	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Aim 1 
Atherosclerosis, the leading cause of mortality in industrialized countries, is the 
principal process contributing to the pathogenesis of coronary artery disease (CAD) 
and acute myocardial infarction (AMI). Most CAD cases are multifactorial in 
aetiology, involving numerous environmental and heritable risk factors. Inflammation 
is a crucial component in the development, progression and disruption of the 
atheroma. Indeed, many of the genes that have been implicated until now in CAD are 
involved in innate and adaptive immunity. Thus, PTX3 was a good candidate gene to 
study its involvement in atherosclerosis and in its major life threatening complication, 
AMI. Actually, PTX3 has cardio- and athero-protective functions and is a diagnostic 
and prognostic marker of cardiovascular disease. 
In the present work, we addressed the eventual association of PTX3 single 
nucleotide polymorphisms with PTX3 plasma levels and the risk of developing AMI 
in a Caucasian population. 
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Materials and methods 
Study population 
Three PTX3 SNPs were analysed in a Caucasian population of 3245 subjects 
recruited by four participating units (Table 1): Istituto Clinico Humanitas (Rozzano, 
MI), Istituto di ricerche farmacologiche "Mario Negri" (MI), Istituto "Casa Sollievo 
della Sofferenza" (San Giovanni Rotondo, FG) and Ospedale “Francesco Lastaria” 
(Lucera, FG) in Italy. 
The population was stratified into two diagnostic groups: the case group (1751 
subjects) and the control group (1494 subjects). Patients of the first group had an 
acute myocardial infarction with ST elevation (AMI) and they presented at least one 
conventional coronary risk factor, such as cigarette smoking, hypertension (systolic 
blood pressure higher than 150 mm Hg or diastolic blood pressure higher than 85 mm 
Hg), diabetes mellitus (blood glucose level ≥ 126 mg/dL), hypercholesterolemia (total 
serum cholesterol level ≥ 200 mg/dL), dislipidemia (low density lipoprotein ≥ 130 
mg/mL or high density lipoprotein ≤ 40 mg/dL or triglycerides ≥ 150mg/dL) and one 
relative with CAD minimum. Conversely, the control subjects did not have history of 
CAD, but at least one of the previously mentioned coronary risk factors. In this last 
group, a smaller subgroup of 362 subjects was further identified through coronary 
angiography that showed healthy coronaries characterized by the absence of stenosis 
and/or wall abnormalities. This subgroup of controls underwent coronary angiography 
before a cardio-surgical intervention for valvular disease (i.e. aortic or mitral 
regurgitation or stenosis). 1448 subjects out of 2458 provided by Istituto "Mario 
Negri" were from the GISSI-Prevenzione trial. The clinical data and the baseline 
characteristics of this population have been previously described289. Briefly, the 
GISSI-prevenzione, an open controlled clinical trial, was conducted on patients 
surviving beyond the hospital phase of AMI. Its objective was the evaluation of 
pharmacological treatments aimed to improve the profile of AMI patients, in terms of 
survival and quality of health. The age of all the subjects included in the case study 
ranged between 45 and 65 years. 
Venous blood samples (5 mL in ethylenediaminetetraacetic acid) were collected 
from all the adult subjects that signed an informed consent to the study. 
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DNA extraction, sequencing and genotyping 
Genomic DNA extraction was performed from frozen blood using QIAamp DNA 
Blood Mini Kits (Qiagen), following the manufacturer's protocol. DNA purity and 
concentration were evaluated using Thermo Scientific NanoDrop™ 1000 
Spectrophotometer. 
DNA samples of 50 cases and 50 controls recruited by Istituto Clinico Humanitas 
were used for the amplification of the entire PTX3 coding sequence and of 
intron/exon boundaries by Polimerase Chain Reaction (PCR). PCR products were 
purified using the Wizard SV gel and PCR Clean-up system (Promega). For the 
subsequent sequencing reactions the Big Dye Terminator v1.1 Cycle Sequencing 
(Applied Biosystems, Foster City, CA) was used. The automated sequencing was 
performed on the ABI 3100 automated sequencer. The same primers were used for the 
amplification and the sequencing of PTX3 exon 1 (FW: 5’-
CTCCGCTCAAACTCAGCTC-3’; REV: 5’-GGTGGATATGTAGTCAGGGTTAG-
3’), exon 2 (FW: 5’-AGGTCAGCTTTTACAAAGCACA-3’; REV: 5’-
TAGAAGGTTGCCTGGCTTG-3’) and exon 3 (FW: 5’-CGTAATGTA 
GGGTTTCACATAGC-3’; REV:5’-CACTGAGTTTTCAGACCTTCCC-3’). 
For the large-scale genotyping the 7900 Real-time PCR System (ABI) was used. 
Real-time PCRs were carried out in a volume of 25µl containing TaqMan Genotyping 
Master Mix, specific TaqMan®SNP genotyping Assays purchased from Applied 
Biosystems (ABI, Foster city, CA) and 20 ng of genomic DNA, according to the 
manufacturer’s instructions. The fluorescent data files for each plate were analysed 
using Sequence Detection System version 3.2 (ABI, Foster city, CA). To ensure the 
quality of automatic allele calling, all samples were analysed in two replicates, and 
the concordance rate was 100%. No genotype data were missing. 
PTX3 dosage 
Plasma-EDTA PTX3 levels were measured by an enzyme–linked immunosorbent 
assay (ELISA) from Perseus Proteomics Inc. (Tokyo, Japan)104. 
PTX3 levels were measured in 704 AMI patients (from GISSI-Prevenzione trial) 
and 664 controls. For AMI patients, blood was collected al least 5 days after the onset 
of symptoms of the last event (the index event or a later event during the follow-up). 
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In AMI patients, PTX3 plasma levels return to normal values 125 hours after 
symptom onset290. 
PTX3 levels from 76 controls were excluded from the analysis because blood was 
sampled too close to coronarography. Moreover, PTX3 levels of 7 controls were set to 
missing values because they were greater than 99th centile, corresponding in our 
sample to a PTX3 level of 10 ng/mL. Finally, PTX3 levels from 4 AMI patients were 
kept out from the analysis because blood was sampled before the time needed for 
normalization after the last event290. The 5% (87/1455) of available PTX3 levels were 
excluded from the analysis.  
Statistical analysis 
Continuous variables were compared among groups using Student t test, ANOVA 
or Kruskall Wallis rank test as appropriate. Differences in percentages were assessed 
by Chi-square test.  
The pairwise LD among the three SNPs was assessed by the correlation 
coefficient R2. For each SNP, a Chi-square test was done to assess whether the 
observed genotype frequencies were in Hardy Weinberg Equilibrium (HWE) among 
controls. HWE was tested using the genhw STATA package. 
Frequency distributions by genotype and by minor allele were compared across 
groups. Odds ratios (OR) and 95% confidence intervals (CI) were calculated 
comparing AMI group with the controls. A codominant genetic model has been 
tested. 
In order to quantify the association between each SNP genotypes, diagnostic 
groups and PTX3 levels, a linear regression model was fitted, including age and sex 
as covariates. The interaction of each SNP with the diagnosis on PTX3 levels was 
evaluated by adding product terms to a multiple regression linear model, adjusted by 
age and sex. 
Haplotype frequencies for rs2305619, rs3816527 e rs1840680 SNPs have been 
estimated by EM algorithm using UNPHASED 3.1291. Rare haplotypes 
(frequency<0.05) have been ignored. 
A multivariable logistic regression model was used to determine, after adjusting 
for sex, age and other available clinical covariates, the effect of PTX3 level on the 
risk of death, cardiovascular death and reinfarction among AMI patients. 
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A p-value < 0.016 was considered significant to adjust for multiple testing across 
the three SNPs. 
Statistical analysis was done using STATA 9.0 (http://www.stata.com).  
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Results 
Association between risk of AMI and PTX3 genetic variants 
The population sample analysed in our study was composed of 3245 Italian 
subjects, including 1751 AMI patients and 1494 controls. Among the controls, 362 
underwent coronary angiography and exhibited undamaged coronaries. 
The baseline characteristics of our case study are shown in Table 2: age, sex, 
BMI (Body Mass Index) and lipids are described separately for AMI patients and 
controls. The case and control populations were very homogeneous in terms of age, 
whereas among AMI patients more males were present than females. As expected, 
control subjects had significantly higher HDL cholesterol levels and significantly 
lower levels of triglycerides than AMI patients. BMI and LDL cholesterol did not 
vary significantly between AMI and controls. 
To identify PTX3 genetic variants present in the Caucasian population, we 
performed a screening of the entire PTX3 coding sequence and of intron/exon 
boundaries in 100 subjects of the case study (50 controls and 50 cases). The sequence 
analysis of amplified regions revealed the presence of three SNPs (Fig. 1). Two of 
them were located in the intronic sequence of PTX3 gene (rs2305619 in intron 1 and 
rs2316706 in intron 2), whereas the third, rs3816527 in exon 2, was responsible for an 
amino acid change in position 48 (Asp48Ala), leading to a change in PTX3 primary 
structure. 
Because the rs2305619 and rs2316706 SNPs were in complete Linkage 
Disequilibrium (LD, R2 = 1), we performed the large-scale genotyping only testing the 
intronic rs2305619 and the exonic rs3816527 SNPs. A third polymorphism 
(rs1840680) was included in our analysis in line with previous association studies on 
PTX3 genetic variants. Indeed, rs2305619, rs3816527 and rs1840680 are the three 
SNPs of the GAG haplotype which have been correlated with an increased 
susceptibility to Mycobacterium tuberculosis and Pseudomonas aeruginosa 
infections107,109 and with an increased fertility112. 
Genotyping was complete for all individuals. Genotype and allele frequencies 
among controls of rs2305619, rs3816527 and rs1840680 SNPs are represented in Fig. 
2. Information about rs2305619, rs3816527 and rs1840680 SNPs are reported in 
Table 3. Genotype frequencies of all the SNPs analysed resulted in Hardy-Weinberg 
Equilibrium (HWE) among controls (p=0.97, p=0.32, p=0.98 for rs2305619, 
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rs3816527 and rs1840680, respectively). The minor allele frequencies (MAF) resulted 
similar to the frequencies reported in HapMap. Both rs3816527 and rs1840680 SNPs 
were high correlated with the first polymorphism rs2305619 (R2=0.7, R2=0.9, 
respectively). 
Genotype frequencies of the three analysed SNPs (Table 4) as well as haplotype 
frequencies were compared between AMI patients and controls or angiographically 
controlled individuals. None of genotypes or haplotypes was significantly associated 
with susceptibility to AMI. 
 
 
Table 1 | Distribution of cases and controls among recruitment centres. 
Institute Tot AMI Controls 
Controls with 
undamaged 
coronaries 
Istituto Clinico Humanitas 
and Tor Vergata 
597 299 298 268 
Istituto "Casa Sollievo della 
Sofferenza"  
94 0 94 94 
Ospedale "Francesco 
Lastaria"  
96 0 96 0 
Istituto "Mario Negri" 2458 1452 1006 0 
Tot 3245 1751 1494 362 
 
 
Table 2 | Main clinical characteristics of the case and control populations. 
    AMI (N=1751) Controls (N=1494) p-value 
Sex % male 81.8 71.8 <0.001 
Age (years) Mean (SD) 58.1 (7.9) 58.3 (8.1) 0.5 
BMI (Kg/m2)  Median (IQR) 26.4 (24.3,29.0) 26.4 (24.2,28.9) 0.4 
LDL (mg/dL)  Median (IQR) 107.0 (85.0,132.5) 115.0 (97.0,140.5) 0.01 
HDL (mg/dL)  Median (IQR) 40 (33,48) 54 (46,64) 0.0001 
Triglycerides (mg/dL)  Median (IQR) 145 (107,193)  107 (78,146) 0.0001 
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Figure 1 | PTX3 gene details. Gene map with position of SNPs typed and inter-marker 
distances. 
Figure 2 | Genotype and allele distribution of rs2305619, rs3816527 and rs1840680 SNPs in 
the group of control. 
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Table 3 | SNPs information. 
SNPs Position (bp) 
HWE Chi-
square test 
(p-value) 
Minor allele  MAF MAF HapMap R
2 
rs2305619 157154861 0.97 A 0.48 0.508 reference 
rs3816527 157155314 0.32 C 0.43 0.403 0.7 
rs1840680 157156029 0.98 A 0.48 0.491 0.9 
 
Table 4 | Distribution of rs2305619, rs3816527 and rs1840680 SNP genotypes between AMI 
and controls. 
   AMI  Controls   
SNP Genotype N=1751 N=1494 p-value 
rs2305619 AA 400 (22.49%) 359 (24.03%) 0.68 
 AG 871 (49.94%) 746 (49.93%)  
  GG 473 (27.12%) 389 (26.04%)  
     rs3816527 CC 310 (17.74%) 292 (19.58%) 0.39 
 AC 864 (49.46%) 714 (47.89%)  
 AA 573 (32.80%) 485 (32.53%)  
     rs1840680 AA 395 (22.75%) 355 (23.76%) 0.72 
 AG 867 (49.94%) 746 (49.93%)  
  GG 474 (27.30%) 393 (26.31%)   
 
Association between PTX3 plasma levels and PTX3 genetic variants 
Next, we evaluated the possible effect of the three SNPs on PTX3 plasma levels 
in the two diagnostic groups. In literature, it has been reported that PTX3 levels in 
blood are associated with age and sex290,292. In our case study a significant increase of 
PTX3 concentrations has been found in association with age (β=0.02; p=0.002), but 
not with sex. PTX3 concentrations were measured in 1368 subjects, including 704 
AMI patients (from GISSI-Prevenzione trial) and 664 controls. PTX3 plasma levels 
(mean ± SD) resulted significantly higher in AMI patients (3.61 ± 2.43 ng/mL) than in 
controls (2.93 ± 1.52 ng/mL, p=0.0001). For AMI patients, the distribution of PTX3 
levels according to the time of blood collection is reported in Fig. 3. The blood was 
sampled in a period spanning from 5 to 733 days from the last event and three ranges 
of time were identified: the first spanning from 5 to 63 days, the second from 64 to 
184 days and the third from 185 to 733 days. For each time range, the mean of PTX3 
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concentration was measured. In the first range, PTX3 levels (4.18 ng/mL) were 
significantly different (p<0.0001) from PTX3 values in the second (3.31 ng/mL) and 
in the third range (3.33 ng/mL). No differences were found in the distribution of PTX3 
genotypes among the three groups generated according to the time of blood 
collection. 
The distribution of PTX3 plasma levels among rs2305619, rs3816527 and 
rs1840680 genotypes is shown in Table 5. In control patients, PTX3 levels were 
significantly different among genotypes for all the three SNPs. PTX3 levels in AMI 
patients showed the same trend, although differences were not significant. In 
particular, the carriers of the AA genotype at the rs2305619 SNP had the higher 
amount of PTX3 in the blood compared to the AG and GG carriers. The same data 
were obtained for the AA genotype carriers at the intronic polymorphism rs1840680 
and for the CC genotype carriers, in controls, and the AC genotype carriers, in AMI 
patients, at the exonic polymorphism rs3816527. 
Fitting a linear regression model, adjusted by age and sex, both the genotype and 
the diagnosis (AMI vs controls) resulted significantly associated to PTX3 plasmatic 
levels for all the three SNPs (p=0.0083, p=0.0347, p=0.0032, respectively for 
rs2305619, rs3816527 and rs1840680). PTX3 genetic variants did not associate with 
the diagnosis, suggesting the presence of a correlation between PTX3 levels and 
PTX3 SNPs that is independent of the pathological condition (Fig. 4). 
Moreover, the possible association between PTX3 plasma levels and haplotypes 
in the entire population (AMI patients and controls) was evaluated. Like each 
individual SNP, the haplotypes were associated with different PTX3 plasma levels 
(overall p-value=0.01, Table 6). Additive values estimated the change in the expected 
value of PTX3 plasma levels due to a given haplotype. These additive values were 
small but significant. AAA (for rs2305619, rs3816527 and rs1840680, respectively) 
and ACA haplotypes were associated with an increased value of PTX3 levels when 
compared to the most common GAG haplotype that was considered as reference. The 
ACA haplotype (frequency = 42%) was associated with an estimated increase in 
PTX3 plasma levels of 0.05 ng/mL, whereas for the AAA haplotype (frequency = 
5%) this estimated increase was of 0.08 ng/mL compared with the GAG haplotype 
(frequency = 52%). 
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Figure 3 | Distribution of PTX3 plasma levels in AMI patients according to the time of blood 
collection after the last event. For 704 AMI patients (from GISSI-Prevenzione trial), PTX3 plasma 
levels (ng/mL) were measured at different time points, from 5 to 733 days, after the last event. Three 
main time ranges can be identified: the first from 5 to 63 days, the second from 64 to 184 days, the 
third from 185 to 733 days. 
Table 5 | PTX3 plasma levels distribution among SNP genotypes in AMI patients and 
controls. 
    IMA (N=704)   Controls (N=664) 
   PTX3 (ng/mL)   PTX3 (ng/mL) 
SNP Genotype N Mean (SD)   N Mean (SD) 
rs2305619 AA 154 3.84 (2.58)  152 3.22 (1.60) 
 AG 344 3.67 (2.54)  352 2.84 (1.49) 
 GG 206 3.32 (2.11)  160 2.83 (1.47) 
 p-value  0.08   0.02 
       
rs3816527 CC 118 3.56 (2.07)  126 3.22 (1.54) 
 AC 344 3.80 (2.74)  331 2.90 (1.54) 
 AA 242 3.36 (2.10)  207 2.79 (1.46) 
 p-value  0.15   0.02 
       
rs1840680 AA 154 3.89 (2.60)  149 3.25 (1.61) 
 AG 340 3.66 (2.54)  355 2.83 (1.49) 
 GG 210 3.31 (2.10)  160 2.83 (1.47) 
  p-value   0.06     0.009 
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Figure 4 | Interaction plot of the estimated PTX3 mean levels, adjusted by sex and age, 
according to diagnosis by rs2305619, rs3816527 and rs1840680 genotypes. In each graph, the 
estimated mean of PTX3 levels (ng/mL) in the two diagnostic groups (—n— AMI patients, ---- 
controls) according to genotypes is represented. 
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Table 6 | Association between common haplotypes of SNPs rs2305619, rs3816527 and 
rs1840680 and PTX3 levels. 
Haplotype Count Frequency Additive value (ng/mL) 
95% CI 
(ng/mL) 
GAG 1427 0.52 reference reference 
ACA 1162 0.42 0.05 0.009-0.08 
AAA 138 0.05 0.08 0.009-0.158 
 
Association between PTX3 plasma levels and prognosis 
Next, we assessed the role of PTX3 genetic variants in the prognosis of AMI 
patients in a retrospective analysis. Among 1448 AMI patients from the GISSI-
Prevenzione trial, 120 deaths (8.29%), 32 cardiovascular deaths (2.21%) and 64 
reinfarctions (4.42%) have been counted. Blood for PTX3 dosage was available only 
for 68 out of 120 deaths, 19 out of 32 cardiovascular deaths and 32 out of 64 
reinfarctions. In patients with en event occurring over 3 years after the index event the 
age was significantly higher (p<0.0001 for death, p=0.002 for cardiovascular death, 
p=0.02 for reinfarction) than in event-free subjects. Cardiovascular deaths were 
significantly more frequent among females (p=0.03) than in males. Other clinical 
covariates as well as SNP genotypes were not associated with events. After an 
adjustment by age and sex, PTX3 levels correlated with the risk of death (p=0.02, 
OR=1.10, 95% CI: 1.10-1.20), whereas the association was not significant for 
cardiovascular death (p=0.09, OR=1.12, 95% CI: 0.98-1.27) and reinfarction (p=0.67, 
OR=1.03, 95% CI: 0.90-1.18). The distribution of the events was not statistically 
different amongst the three groups identified according to the time of blood collection 
(Fig. 3). 
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Discussion 
In this study, we examined the role of PTX3 genetic variations in the 
susceptibility to AMI. PTX3 gene encodes for the long pentraxin PTX3, a molecule 
involved in the inflammatory response and associated with cardio- and athero-
protective functions. Data obtained in different in vivo models showed that PTX3 is 
involved in modulating inflammation in AMI and atherosclerosis56,85. Moreover, it 
represents a useful diagnostic and prognostic marker in cardiovascular pathology83. 
Despite its strong evolutionary conservation, recent studies have reported the 
presence of a certain number of SNPs in the PTX3 gene. Interestingly, some of these 
polymorphisms, especially when associated in particular haplotypes, have been 
related to clinical conditions, including infections and fertility107,109,112. 
Multiple genetic and/or environmental factors are supposed to play a role in 
conferring variable susceptibility to AMI. The association study reported here reveals 
that 3 common PTX3 polymorphisms do not have a significant effect in modulating 
the risk of AMI in the Caucasian population. 
However, PTX3 SNPs, as well as the haplotypes corresponding to SNPs 
rs2305619 to rs1840680, are associated with different levels of PTX3 in the blood. 
Actually, in our case study the most frequent GAG haplotype is associated with the 
lower value of plasma PTX3 compared to the ACA (+0.05 ng/mL) and AAA (+0.08 
ng/mL, overall p-value = 0.01) haplotypes. The GAG haplotype has been previously 
associated with a protective effect against pulmonary tuberculosis in West Africans107 
and Pseudomonas aeruginosa colonization in Italian cystic fibrosis patients109. 
Moreover, May et al.112 associated the GAG haplotype not only with an increased 
fertility, but also with an increased ex-vivo LPS-induced PTX3 production by whole-
blood cells in a population from Ghana. The apparent conflict of our data with that of 
May and coworkers can be explained by genetic background heterogeneity (with 
different populations having different genetic variants affecting PTX3 levels) and by 
the conditions of PTX3 production taken into account. Actually, May at al. induced 
the ex-vivo production of PTX3 by stimulating whole-blood cells with LPS, whereas 
our data concern the basal PTX3 plasma levels. In particular, in this study PTX3 
values have been excluded from the analysis when plasma for PTX3 dosage have 
been sampled too close to the coronarography, in controls, or before the time for 
normalization after the last event in AMI patients. 
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The mechanism underlying the modulation of PTX3 plasma levels by PTX3 
SNPs has to be clarified yet. It is possible that the PTX3 polymorphisms rs2305619, 
rs3816527 and rs1840680 belong to a larger haplotype block than the one considered 
here and they could be in linkage with a genetic variant located in a regulatory region, 
possibly the PTX3 promoter. We envision that, in such a position, a polymorphism 
can affect the binding of a transcription factor to its consensus binding site, modifying 
the PTX3 expression level. It cannot completely be ruled out that PTX3 SNPs are 
related to higher plasma levels of a functionally less active protein. Actually, the 
second SNP studied here (rs3816527) causes an amino acid change (Asp48Ala) in a 
strategic position of PTX3 primary structure. This substitution can potentially 
interfere with the N-terminal-mediated binding of PTX3 to its ligands. Moreover, the 
amino acid 48 is located between the two cysteine residues (in position 47 and 49, 
respectively) involved in the formation of inter-chain disulfides required for the 
tetrameric arrangement of four PTX3 protomers2. Despite a different isoelectric point 
(pI) between the polar aspartic acid and the non-polar alanine (pIAla=6.11, pIAsp=2.85), 
the pI of PTX3, calculated using the EXPASY bioinformatics tool,293 is quite similar 
comparing the protein carrying the aspartic acid or the alanine residue in position 48 
(4.90 vs 4.94, respectively). The steric hindrance due to the side-chain of the two 
residues is certainly different between the two PTX3 isoforms and, therefore, could 
affect PTX3 activity. 
It is likely that different levels of PTX3 in the blood depending on genetic 
variants have an influence on the outcome of specific infections. Indeed, it has been 
shown that the GAG/ACA haplotypes are differently associated with susceptibility to 
Mycobacterium tuberculosis107 or Pseudomonas aeruginosa colonisations109, even if 
in these two studies the authors did not address a correlation between PTX3 levels and 
PTX3 haplotypes. It is conceivable that haplotypes affecting PTX3 levels are not 
relevant for the risk of developing AMI. 
In our case study, the mean value of circulating PTX3 in the controls is 2.93 ± 
1.52 ng/mL. This value is significantly different from PTX3 levels in AMI patients 
(3.61 ± 2.43 ng/mL p= 0.0001), even if blood was sampled after at least 5 days from 
the last event, the time needed for normalization of PTX3 concentration290. For the 
group of AMI patients, we analysed the distribution of PTX3 plasma levels in the 
three ranges of time identified after the last event. Up to three months after the last 
event, the mean of PTX3 plasma concentration is higher (4.18 ng/mL) than in a later 
Aim 1 
 
	   83	  
period (3.32 ng/mL, from three months to two years), in which PTX3 plasma levels 
reach values quite similar to that measured in healthy subjects. These data suggest that 
the high PTX3 levels, measured from 5 to 64 days after the last event, are likely 
responsible for the significant difference of PTX3 plasma levels observed between 
AMI patients and controls in our population. These results suggest that in AMI 
patients PTX3 plasma levels return, in few days after the onset of symptoms, to a 
quite normal value that remains higher, than in healthy subjects, for at least three 
months. 
Moreover, our data confirm the already described prognostic value of PTX3 
plasma levels in AMI patients. Latini et al. demonstrated that PTX3 is an independent 
predictor of 3-months mortality, when compared with other biomarkers considered 
reliable predictors of death in patients with AMI91. The retrospective analysis 
conducted in this study on AMI patients from GISSI-Prevenzione trial reveals a 
correlation between PTX3 plasma levels and all-cause death. 
In this study, we provide evidence of a strong association between PTX3 genetic 
variants and PTX3 plasma levels, but we did not observed a correlation between 
PTX3 SNPs, responsible for a different baseline PTX3 concentration in the blood, and 
susceptibility to AMI (Fig. 5). A similar set of data has been obtained for another 
member of the pentraxin superfamily, the C-reactive protein. CRP, like PTX3, binds 
LDL16 and is present in the atherosclerotic plaque17. Several epidemiological studies 
of coronary heart disease (CHD) have reported an association of increased basal CRP 
levels and CHD risk30,31. Altogether these observations suggested the possible causal 
role of CRP in CHD. Several SNPs have been identified in the CRP gene. 
Independently or combined in haplotypes, part of these SNPs was associated with 
different CRP baseline levels. Actually, a meta-analysis of genetic studies involving a 
new Bayesian method (enabling integration of information across studies that had 
typed a partially overlapping set of CRP SNPs) has provided evidence of four 
functional SNPs at the CRP locus that influence its circulating concentration40. A 
debate about the relationship between the genetically determined CRP blood levels 
and the risk of CHD has been opened for years. Randomized treatment trials specific 
to CRP have not yet been done in relation to cardiovascular outcomes. Therefore, 
genetic studies based on the “Mendelian randomisation” approach have been used to 
evaluate the causal relevance of CRP itself to CHD. Data obtained from large case 
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studies suggest that CRP concentration itself is unlikely to be even a modest causal 
factor in CHD39,42. 
Given our results on PTX3 and evidences on CRP in relation to CHD risk, we 
envision a similar situation for PTX3 and AMI risk. Actually, this study highlights the 
role of PTX3 SNPs in modulating PTX3 baseline levels that, after a peak, remain 
higher in patients that underwent an AMI than in healthy subjects. When we evaluated 
the association of PTX3 SNPs with the risk of AMI, we did not obtain a significant 
correlation. Indeed, PTX3 is a marker of atherosclerosis and correlates with the risk of 
cardiovascular events, but genetically determined high PTX3 levels do not seem to 
increase the susceptibility to AMI. 
Figure 5 | Schematic representation of results obtained. PTX3 single nucleotide 
polymorphisms (rs2305619, rs3816527 and rs1840680) correlate with different levels of PTX3 in the 
blood. High PTX3 plasma levels are observed in CVD/AMI patients. The candidate gene association 
analysis performed here did not reveal an association between PTX3 SNPs and the risk of developing 
AMI. 
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Aim 2 
As new regulators of gene expression, microRNAs have a great impact on protein 
expression of specific targets. As all “conventional” genes, their expression can be 
regulated in response to stimuli involved in almost all physiological and pathological 
processes, including inflammation. Actually, the up-regulation of a single miRNA or 
of a miRNA set can switch off a complete signalling pathway, by targeting receptors, 
adaptors, signalling molecules, transcription factors and regulators. 
PTX3 production is induced in different cell types by different stimuli and we 
assessed whether its expression could be regulated at the post-transcriptional level by 
specific miRNAs. 
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Materials and Methods 
Cell cultures and reagents 
8387 human fibrosarcoma cells (ATCC) were cultured at 37ºC with 5% CO2 in 
RPMI supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine and 
antibiotics. HEK293T, Human Embryonic Kidney 293 cells stably and constitutively 
expressing the SV40 large T antigen (ATCC), were cultured at 37ºC with 5% CO2 in 
DMEM supplemented with 10% FBS, 2 mM L-glutamine and antibiotics. 
RPMI 1640 and DMEM medium, 200 mM Ultraglutamine-1 (100x), 10000 
U/mL Penicillin-Streptomycin solution (100x) and FBS were purchased from Lonza. 
Recombinant human cytokines were obtained from PeproTech (Neuilly-Sur-Seine, 
France). LPS from Escherichia coli serotype R515 (RE) (~99.9% purity) was 
obtained from Alexis. 
Constructs generation and Luciferase Reporter Assay 
The pBlueScript vector containing the entire human PTX3 3’ untranslated region 
(3’ UTR) was used as DNA template for performing a PCR with the M13 primer (5’-
TGTAAAACGACGGCCAGT-3’) and the following primer containing 8 additional 
nucleotides at the 5’-end, six of which (underlined) give rise to a SpeI restriction site 
(5’-GAACTAGTATGTTGTGAAACTCCACTTG-3’). The PTX3 3’UTR was 
excised by SpeI-XhoI digestion and subcloned in SpeI-XhoI-digested psiCHECK-2 
vector (Promega, Rluc-PTX3). The ERp18 3’ UTR was entirely cloned in 
psiCHECK-2 vector (Rluc-ERp18) by PCR cloning from a healthy donor genomic 
DNA (primer FW: 5’-GGGTGATGCCTTCAGAAAGA-3’; primer REV: 5’-
CCCTCCCTCCTTTTCCAATA-3’). Site-directed mutagenesis reactions were 
conducted using the QuikChange II XL Site-Directed Mutagenesis Kit from Agilent 
Technologies (USA) in accordance with data sheet instructions. The following 
constructs were generated with mutated (underlined region) oligonucleotides: Rluc-
mut-9-PTX3 (FW: 5’-CTCCACTTGAAGCGGGGGAAAGAAACTCACACT-3’; 
REV: 5’-AGTGTGAGTTTCTTTCCCCCGCTTCAAGTGGAG-3’), Rluc-mut-29-
PTX3 (FW: 5’-CTAGACTTTATGCCAGCCGCCTTTCAGTTTAATGC-3’, REV: 
5’-GCATTAAACTGAAAGGCGGCTGGCATAAAGTCTAG-3’), Rluc-2614-PTX3 
(FW: 5’-TATGCCATGGTGCTTTTAGTTTAATGCTGTGTCTCTG-3’; REV: 5’-
CAGAGACACAGCATTAAACTAAAAGCACCATGGCATA-3’), Rluc-mut29-
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rs2614-PTX3 (FW: 5’-ATGCCAGCCGCCTTTTAGTTTAATGCTGTGTC-3’; REV: 
5’-GACACAGCATTAAACTAAAAGGCGGCTGGCAT-3’), Rluc-mut-181-ERp18-
8mer (GTCAACTTGTCATTGCGCCGAAAGAATGAAACCTTC-3’; REV: 5’-
GAAGGTTTCATTCTTTCGGCGCAATGACAAGTTGAC-3’), Rluc-mut-181-
ERp18-8/7mer (FW: 5’-GATGAATTGTAACATGCGGCTGCCCCTTCTTTCAT-3’; 
REV:5’-ATGAAAGAAGGGGCAGCCGCATGTTACAATTCATC-3’). All the 
generated clones were sequenced and subsequently used in the Luciferase Reporter 
Assay. 
pGV-B2 plasmid expressing firefly luciferase protein under the control of human 
PTX3 promoter was obtained as previously reported59. pRL-TK vector, that expresses 
renilla luciferase gene under an eukaryotic constitutive promoter (HSV-thymidine 
kinase promoter), was used as internal control. 
For the Luciferase Reporter Assay, HEK293T cells were plated in 24-well plates 
in DMEM supplemented with 10% FBS, 2 mM L-glutamine and without antibiotics 
to avoid possible interference with lipofectamine 2000 (Invitrogen), used for cell 
transfection. 8 x 104 cells were plated in each well 24 h before transfection. To study 
the direct interaction miR:3’UTR, cells were co-transfected with 100 ng of 
psiCHECK-2 vector (Rluc construct) together with miRNA precursors or miRNA 
negative control (mimics, from Ambion) to reach 100 nM as final concentration. To 
investigate the activity of miRNAs on the signalling cascade upstream PTX3 promoter 
activation, cells were co-transfected with 50 ng of pGV-B2, 50 ng of pRL-TK and 
pre-miR or miRNA scramble to reach a final concentration of 100 nM and cells were 
stimulated or not with TNFα or IL-1β (both obtained from Peprotech). After 24 hours 
from transfection, cells were lysed and both firefly and renilla luciferase activities 
were determined using the Dual-Glo Luciferase Assay System (Promega). The 
enzymatic activities of the luciferases were quantified using a MultiDetection 
Microplate Reader Synergy 2 luminometer (BioTek). The use of psiCHECK-2 vector 
enables the detection of changes in the expression of the target gene (3’UTR) fused to 
a primary reporter gene (renilla luciferase, R-luc). The second reporter gene (firefly 
luciferase, Luc) is used as an internal control, allowing for the normalization of R-luc 
expression. Results obtained from R-luc constructs and mimics co-transfection are 
expressed as mean ± SEM of the ratio between renilla luciferase and firefly control 
luciferase activities (RLU) adjusted to 1. Each experiment was conducted in triplicate. 
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Results obtained from pGV-B2, pRL-TK and mimics co-transfecion are expressed as 
mean ± SEM of the ratio between firefly luciferase and renilla control luciferase 
activities (RLU) adjusted to 1. Each experiment was conducted in duplicate. 
8387 Transfection 
Mimic transfection was conducted in 24-well tissue culture plates. 24 h before 
transfection, 8 x 104 8387 cells were plated in complete medium without antibiotics. 
Complexes of lipofectamine 2000 (Invitrogen) and pre-miR or miR-control (Ambion) 
were assembled in Opti-MEM medium (Invitrogen) and added to each well, reaching 
a mimic final concentration of 100 nM. Co-transfection of mimics and siRNA 
molecules (Dharmacon) was performed at a final concentration of 50 nM each. After 
the over-night transfection, medium containing lipofectamine was removed to avoid 
cell death. Cells were stimulated or not with 20 ng/mL TNFα or IL-1β (both from 
Peprotech) in RPMI supplemented with 1% FBS. After 8 and 24 h stimulation, cells 
free supernatants were collected for subsequent PTX3 measurement. Each experiment 
was conducted in duplicate. 
To assess siRNA activity on Erp18 expression, 3x105 8387 cells were pleated one 
day before transfection in a 6-well plate and siR-Erp18 (ON-TARGET plus SMART 
pool siRNA, Dharmacon) or siR-control (ON-TARGET plus Non-targeting siRNA, 
Dharmacon) were transfected using lipofectamine 2000 reagent (Invitrogen) at a final 
concentration of 100 nM. After 24 h, cells were collected and lysed with Trizol or 
Protein Lysis Buffer and mRNA or protein quantified by qRT-PCR or Western Blot 
analysis, respectively. 2 independent experiments were conducted. 
PTX3 dosage 
PTX3 protein released by 8387 cells was quantified from cell free supernatants 
by previously described home-made-ELISA290. In brief, 96-well ELISA plates (Nunc) 
were coated with 100 µg of anti-PTX3 monoclonal antibody (mAb) MNB4 and 
incubated overnight at 4°C. Nonspecific binding sites were saturated with 300 µL of 
5% dry milk (2 hours at 37°C), prior the addition of purified human recombinant 
PTX3 standards (from 75 pg/mL to 2.4 ng/mL) and unknown samples diluted in PBS 
(Cambrex BioScience) and 2% bovine serum albumin (Sigma). After 2 h at 37°C, 100 
ng of biotin-conjugated rabbit polyclonal anti-PTX3 were added to each well. Plates 
were incubated for 1 h at 37°C and streptavidin-peroxidase was then added, followed 
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by the addition of the TMB liquid substrate system (Sigma). After each step, plates 
were extensively washed with PBS (Cambrex Bio Science) containing 0.05% Tween 
20 (Merck), also used for reagent dilution. 
SDS –PAGE and Western Blotting 
For immunoblot experiments, transfected 8387 cells were lysed in Protein Lysis 
Buffer containing 50 mM Tris-HCl (pH 7.5), 2 mM EDTA, 100 mM PMSF, 1% 
Triton X-100 and a cocktail of protease inhibitors (cOmplete, EDTA-free Protease 
Inhibitor Cocktail Tablets, Roche Applied Science, Canada). Protein lysates were 
centrifugated at 16.000xg for 10 min at 4°C and conserved at 4°C to prevent 
proteolysis. The protein content was determined using the Coomassie reagent 
(Thermo Scientific) in accordance with data sheet instructions. 35 µg of total proteins 
from each sample were subjected to electrophoresis in denaturing conditions on 
12,5% SDS-PAGE gels and transferred onto nitrocellulose membranes (Bio-Rad). 
Following the transfer, the membranes were blocked in 5% dry milk for an hour and 
then incubated overnight with the primary antibody at 4°C. The following day, the 
membranes were washed three times with 1x PBS/Tween 20 0.1% and probed with 
the secondary antibody (one hour incubation). Anti-ERp18 rabbit pAb (Abcam Inc.), 
for the detection of ERp18, and anti-Vinculin mouse mAb (Sigma-Aldrich), for 
Vinculin detection, were used at dilution of 1:500 and 1:5000, respectively, in 5% 
milk. The secondary antibodies were horseradish peroxidase-conjugated donkey anti-
rabbit IgG or sheep anti-mouse IgG (GE Healthcare Bio-Sciences AB). ECL reagents 
(from Millipore) were used in accordance with data sheet instructions. Image J 
software from NIH (National Institutes of Health, Bethesda, MD) was used for gel 
band quantitative densitometric analysis. Selected bands were quantified on their 
relative intensities. Data are expressed as mean ± SEM of the ratios between ERp18 
and Vinculin band intensities (AU) adjusted to 1. 
Real time RT-PCR (RT-qPCR) 
The expression of Erp18 gene was quantified by RT-qPCR. Total RNA of 8387 
cells transfected with siR-Erp18 or siR-control was extracted using the TRIzol 
method according to the manufacturer’s instructions (Invitrogen). RNA purity and 
concentration were evaluated using Thermo Scientific NanoDrop™ 1000 
Spectrophotometer. 1 ?g of total RNA from each sample was reverse transcribed 
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using the high capacity cDNA Reverse Transcription kit (Applied Biosystems) 
according to the manufacturer’s protocol. Erp18 gene expression was quantified by 
RT-qPCR performed in duplicate from 20 ng cDNA in the presence of the SYBR 
green PCR Master Mix (Applied Biosystems) and 400 nM of the specific 
oligonucleotides (FW:5’-GGTAAATCTTGAGGATGAAGAGGA-3’; REV:5’-
TGTTTCTTTCTGAAGGCATCAC-3’). RT-qPCR data were analysed with SDS 
2.2.1 software and normalized on the expression of GAPDH expression (FW: 5’-
AACAGCCTCAAGATCATCAGC-3’; REV: 5’-GGATGATGTTCTGGAGAGCC-
3’). RT-qPCR reaction was conducted using the Applied Biosystems 7900HT Fast 
Real-Time PCR System. Thermal cycler conditions were the following: 95 °C for 20 
s, 40 cycles of 95 °C for 1 s and 60 °C for 20 s. 
Statistical Analysis 
Data are expressed as means ± SEM. Statistical changes in luciferase expression 
and in PTX3 production were determined using the one-way ANOVA with α set to 
0.05 according to the Dunnett test. In the densitometric analysis of Western blots, 
statistical changes were determined performing a Student’s t test. ***: p < 0.001; **: 
p < 0.01; *: p < 0.05; ns: p > 0.05. 
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Reesults 
miR-9 and miR-29 affect PTX3 production via direct control at post-
transcriptional level 
In order to identify microRNAs potentially involved in the regulation of PTX3 
expression, we analysed the human PTX3 3’ UTR using TargetScan294 and 
MiRanda295 software. As shown in Fig. 6A, the human PTX3 mRNA presents well 
conserved 7-mer long seed regions for miR-9 and miR-29, located 24 and 204 bp 
downstream the stop codon, respectively. Both seed regions were evolutionarily 
conserved in mammals, but not in birds. (Fig. 6B). The ability of miR-9 and miR-29, 
which is a family composed by three members (miR-29a, miR-29b, miR-29c), to 
directly interact with the PTX3 3’ UTR, was then evaluated in a luciferase-based 
reporter assay. HEK293T cells were transiently co-transfected with the reporter 
construct containing the renilla luciferase coding sequence fused to the whole human 
PTX3 3’ UTR and 100 nM pre-miR-9 or pre-miR-29abc. As shown in Fig. 6C, miR-9 
and miR-29abc reduced renilla luciferase activity by approximately 50% in 
comparison to the scramble control. When we mutated the miR-9 seed region on 
PTX3 3’ UTR, the luciferase expression was restored, attesting the specificity of miR-
9 base-pairing with PTX3 3’ UTR. The same was also demonstrated for all the 
members of the miR-29 family, since the mutagenesis of miR-29 seed region reverted 
the inhibitory activity of miR-29abc. 
These data suggest that miR-9 and miR-29 display a strong regulation of PTX3 
mRNA directly acting on the target sites predicted by bioinformatic tools. 
The human 8387 fibrosarcoma cell line constitutively produce PTX3 and 
upregulates its production in response to TNFα and IL-1β (Fig. 7 and ref. Doni et al. 
59). To test whether miR-9 and miR-29 family members affected PTX3 production at 
the protein level, 8387 cells were transfected with pre-miR-9 or pre-miR-29abc and 
PTX3 production was analysed by ELISA290,296. As shown in Fig. 8, miR-9 and miR-
29 family members significantly down regulated PTX3 production compared to 
control cells at the basal level and after stimulation with TNFα and IL-1β. Notably, in 
basal conditions 8387 cells transfected with pre-miR-9 produced half amount of 
PTX3 than mock cells. 
These results demonstrate that miR-9 and miR-29 operate a negative regulation 
on PTX3 at the post-transcriptional level affecting the protein production. 
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The PTX3 gene presents the single nucleotide polymorphism (SNP) rs2614C>T 3 
bp downstream the miR-29 seed region (Fig. 6A). The Haplotype Mapping Project 
database reported a frequency for the C allele of 99% in European and 90% in Sub 
Saharan African subjects, respectively. When the two allelic variants were tested for 
miR-29 activity in luciferase assay, results showed a similar effect of miR-29abc on 
the two 3’ UTR PTX3 sequences (data not shown), indicating that this SNP is not 
interfering with the regulatory role of miR-29abc on PTX3 production.	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Figure 6 | PTX3 is a direct target of miR-9 and miR-29. (A) PTX3 gene has been mapped on 
chromosome 3 (3q25.3) and it is composed of three exons. Its 3’ UTR is 608 bp-long and miR-9 and 
miR-29 seed regions are located 24 and 204 bp downstream the PTX3 mRNA stop codon, respectively. 
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The rs2614 SNP is located three bp downstream miR-29 target site. (B) miR-9 and miR-29 seed 
regions on PTX3 3’ UTR are evolutionary conserved, as shown by TargetScan, in primates and 
mammals in general. (C) HEK293T cells were co-transfected with 100 ng of the indicated luciferase 
constructs (Rluc-vectors) together with 100 nM pre-miR-9, pre-miR-29, or the scramble control (grey 
columns). Results are expressed as mean (± SEM, n=3) of the ratio between renilla luciferase and 
firefly control luciferase activities (RLU) adjusted to 1. ***: p < 0.001; ns: p > 0.05. 
Figure 7 | PTX3 production by 8387 cells. Results are represented as mean (± SEM, n=3) of 
PTX3 released (ng/mL) by 8387 cells without any stimuli (grey column) or treated with TNFα (20 
ng/mL), IL-1β (20 ng/mL) or LPS (100 ng/mL and 1µg/mL). 
Figure 8 | Effect of miR-9 and miR-29 on PTX3 production. 8387 cells were transfected with 
100 nM pre-miR-9, pre-miR-29abc or scramble control. PTX3 production (ng/mL) was measured by 
home-made ELISA and results are represented as mean (± SEM, n=6 for miR-9 and n=3 for miR-
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29abc). (A) Each graph shows the time course of PTX3 production for the considered miR (−−) and 
for the scramble control (----). Graphs on the left are referred to the basal protein production, graphs 
on the right to the TNFα-induced (20 ng/mL) PTX3 production. (B) PTX3 production after 8h of IL-1β 
stimulation (20 ng/mL) is represented in the bar graph. *: p < 0.05, **: p < 0.01, ***: p < 0.001. 
Inflammation-related microRNAs affect PTX3 production via transcriptional 
regulation 
Mononuclear phagocytes are a major source of PTX3 during inflammatory 
responses50,297. At the same time, proinflammatory stimuli induce a distinct set of 
microRNAs in human mononuclear cells, including miR-9, miR-132, miR-146a, miR-
155, miR-187, and the miR-99b∼7e∼125a cluster210,288. Therefore, we investigated the 
potential role of these inflammation-related microRNAs on PTX3 regulation in 
luciferase reporter assay and on its production in 8387 cells transfected with mimics. 
PTX3 basal production was significantly impaired by miR-132. miR-146a and miR-
155 significantly down-regulated PTX3 production in IL-1β and TNFα stimulated 
cells (Fig. 9). The miR-99b∼7e∼125a cluster and miR-187 did not affect PTX3 
production at any condition tested (Fig. 10). Consistent with the lack of corresponding 
seed regions in the PTX3 3’ UTR, apart from miR-9, none of the other miRNAs 
tested was able to affect PTX3 3’ UTR stability in luciferase reporter assay (data not 
shown). 
Since our results indicated that miR-132, miR-146a and miR-155 down-regulated 
PTX3 production without directly targeting PTX3 mRNA, we hypothesized they 
might have an impact on PTX3 transcription. To test this hypothesis, the PTX3 
promoter sequence (gi:1679604) was cloned in the PGV-B2 reporter vector and 
transiently co-transfected with different miRNA precursors in HEK293T cells. 
Consistent with our hypothesis, miR-146a and miR-155 significantly limited the 
PTX3 promoter activity induced by TNFα stimulation, while miR-132 was ineffective 
(Fig. 11). This experiment also highlighted that miR-9 did not interfere with the 
promoter activity, whereas miR-29abc impaired PTX3 promoter activity. This reveals 
two levels of control exerted by miR-29 family members on PTX3 production (Fig. 
11). 
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Figure 9 | Effect of miR-132, miR-146a and miR-155 on PTX3 production. 8387 cells were 
transfected with 100 nM pre-miR-132, pre-miR-146a, pre-miR-155 or scramble control. PTX3 
production (ng/mL) is expressed as mean (± SEM, n=3). (A) In each graph the time course of PTX3 
production is represented for the considered miR (−−) and for the scramble control (----) in basal 
condition (left column) and after TNFα stimulation (20 ng/mL, right column). (B) The bar graph 
displays the PTX3 production after 8h of IL-1β stimulation (20 ng/mL). *: p < 0.05, **: p < 0.01, ***: 
p < 0.001. 
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Figure 10 | Effect of miR-187 and miR-125a-let-7e-miR-99b cluster on PTX3 production. 
8387 cells were transfected with 100 nM pre-miR-187, pre-let-7e, pre-miR-99b, pre-miR125a or 
scramble control. PTX3 production (ng/mL) is represented as mean (± SEM, n=3). (A) Each graph 
shows the time course of PTX3 production for the considered miR (−−) and for the scramble control 
(----).Graphs on the left are referred to the basal protein production, graphs on the right to the TNFα-
induced (20 ng/mL) PTX3 production. (B) PTX3 production after 8h of IL-1β stimulation (20 ng/mL) 
is represented in the bar graph. 
 
Figure 11 | Effect of miR-9, miR-29, miR-132, miR-146a and miR-155 on PTX3 
transcription. 50 ng PGV-B2 vector expressing whole PTX3 promoter sequence fused to the firefly 
luciferase CDS has been co-transfected in HEK293T cells together with 50 ng pRL-TK vector 
expressing renilla luciferase as normalizer and with 100 nM pre-miR-9, pre-miR-29, pre-miR-132, pre-
miR-146a, pre-miR-155 and scramble control. The experiment has been conducted in basal condition 
(A) and upon TNFα (20 ng/mL) stimulation (B). Results are expressed as mean (± SEM, n = 3) of the 
ratio between firefly luciferase and renilla luciferase control activities (RLU) adjusted to 1. *: p < 0.05, 
**: p < 0.01, ***: p < 0.001. 
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miR-181c affects PTX3 production acting at two levels of control 
PTX3 is a complex multimeric protein, whose function requires the correct 
formation of intra- and inter-chain disulphide bonds60,62,96. For PTX3 this function is 
fulfilled by ERp18298, a member of the protein disulphide isomerase (PDI) 
oxidoreductases responsible for catalysing formation, isomerisation and reduction of 
disulphide bridges in the endoplasmic reticulum299. 
Hence, we investigated the possibility of a third level of microRNA-dependent 
regulation of PTX3 production exerted as post-translational regulation via direct 
targeting of ERp18. In silico analysis predicted multiple seeds for miR-181 family 
members in the ERp18 3’ UTR (Fig. 12A). A luciferase reporter assay in HEK293T 
cells was performed to verify the direct interaction of the four miR-181 family 
members with the ERp18 3’ UTR. As shown in Fig. 12B, miR-181 strongly impaired 
Rluc-Erp18 luciferase activity as compared to the scramble control, reducing the 
luciferase expression by approximately 55%. When miR-181 8-mer seed region was 
mutated on ERp18 3’ UTR, the luciferase expression was not completely restored. 
However, it was sufficient that the 7–mer long seed site was mutated in combination 
with the 8-mer seed region, for restoring the luciferase activity. Collectively, these 
data suggest that the 8-mer and 7-mer seed regions in ERp18 3’ UTR are specific sites 
for the interaction miR-181:ERp18 mRNA. 
As miR-181c has been previously related to the inflammatory response, being up-
regulated by LPS in mouse primary macrophages300, we focused our attention on this 
specific member of the miR-181 family. To validate the role of miR-181c on PTX3 
production, 8387 cells were transfected with 100 nM pre-miR-181c and stimulated or 
not with TNFα or IL-1β. miR-181c significantly down-regulated the basal PTX3 
production as well as the protein production induced by TNFα (Fig. 13A) or IL-1β 
(Fig. 13B). To verify whether PTX3 production was impaired by miR-181c through 
its activity on ERp18 mRNA, ERp18 was silenced by ERp18 siRNA. ERp18 mRNA 
silencing was validated by real-time PCR (data not shown), and Western blot analysis 
showed a comparable effect of ERp18 siRNA and miR-181c in down-regulating 
ERp18 (82.8% and 72.8% inhibition, respectively; Fig. 13C). 
The effects of pre-miR-181c and ERp18 siRNA transfection on basal and TNFα-
induced PTX3 production by 8387 cells were then compared (Fig. 14). 24h after 
transfection basal PTX3 production was significantly down-regulated by miR-181c 
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(48%) and only marginally by siR-ERp18 (13%). However, the combination of both 
the interfering RNAs caused a 60% inhibition in basal condition (p<0.01) and a 52% 
inhibition in TNFα-induced PTX3 production (p<0.05). When miR-181c and siR-
ERp18 were transfected independently, TNFα-induced PTX3 production was less 
important (45 and 29%, respectively). At an early time point, the basal PTX3 
production was neither affected by miR-181c, by siR-ERp18 nor by their 
combination. 
Hence, miR-181c targeted ERp18 mRNA leading to an inhibition of ERp18 
protein expression similar to that obtained by the silencing RNA directed against 
ERp18. Nevertheless, this strong activity was not sufficient to explain the down-
regulation of PTX3 production exerted by mir-181c. Actually, siR-ERp18 did not 
cause the same down-regulation of PTX3 obtained with miR-181c. Moreover, miR-
181c and siR-ERp18 exerted an additive effect on PTX3 production, suggesting that 
miR-181c had other targets, than ERp18, involved in PTX3 expression. Hence, we 
tested the activity of miR-181c on the signalling pathway responsible for PTX3 
promoter activation in HEK293T cells. The analysis revealed a miR-181c-dependent 
inhibition of TNFα-induced PTX3 promoter-regulated luciferase expression (Fig. 15). 
Taken together, these results show the ability of miR-181c to regulate PTX3 
expression at two different levels. In fact, it down-modulates the signalling cascade 
responsible for PTX3 transcription and it abolishes the production of ERp18, involved 
in PTX3 folding. 
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Figure 12 | Schematic representation of ERp18 3’ UTR and effect of miR-181 family 
members on it. (A) Schematic representation of the four miR-181 target sites on the ERp18 3’ UTR: 
one 8-mer long and one 7-mer long seed regions are located 300 bp and 25 bp downstream the stop 
codon, respectively. Two additional 6-mer long seed sites are also present in the ERp18 3’ UTR. (B) 
HEK293T cells were co-transfected with 100 ng of the indicated luciferase constructs (Rluc-vectors) 
together with 100 nM pre-miR-181 or scramble control (grey columns). Results are expressed as mean 
(± SEM, n=3) of the ratio between renilla luciferase and firefly control luciferase activities (RLU) 
adjusted to 1. ***: p < 0.001; **: p < 0.01; *: p < 0.05; ns: p > 0.05. 
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Figure 13 | Effect of miR-181c on PTX3 production. (A and B) 8387 cells were transfected 
with 100 nM pre-miR-181c (−−) or scramble control (----) and PTX3 production (ng/mL) in basal 
condition and after TNFα (20 ng/mL, panel A) or IL-1β (20 ng/mL, panel B) stimulation was 
measured. Results are presented as mean (± SEM, n=3). (C) 8387 cells transfected with siR-ERp18, 
miR-181c and respective controls (siR-c and miR-c) were lysed and extracted proteins were loaded on 
SDS-PAGE gel. Nitrocellulose filter was hybridised with pAb-anti-ERp18 or pAb-anti-vinculin as 
normalizer. A Western Blot image of 1 experiment (representative of 2) is reported together with a bar 
graph derived from a densitometric analysis (n=2). **: p < 0.01; *: p < 0.05. 
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Figure 14 | Effect of miR-181c and siR-ERp18 co-transfection on PTX3 production. 8387 
cells were co-transfected with combinations of the indicated small interfering RNAs (50 nM each). 
PTX3 production (ng/mL) was evaluated in basal condition (panel A) and after TNFα stimulation (20 
ng/mL, panel B). Results are expressed as mean (± SEM, n=2). **: p < 0.01; *: p < 0.05. 
Figure 15 | miR-181c activity on PTX3 promoter. 50 ng of PGV-B2 vector expressing the 
whole PTX3 promoter sequence fused to the firefly luciferase CDS has been co-transfected in 
HEK293T cells together with 50 ng pRL-TK vector expressing renilla luciferase as normalizer and 
with 100 nM pre-miR-181c or scramble control. The experiment has been conducted in basal condition 
and upon TNFα (20 ng/mL) or IL-1β stimulation (20 ng/mL). Results are expressed as mean (± SEM, n 
= 3) of the ratio between firefly luciferase and renilla luciferase control activities (RLU) adjusted to 1. 
*: p < 0.05; ns: p > 0.05. 
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Discussion 
PTX3 has been the first long pentraxin to be described in the 1990s and in twenty 
years it has been well characterized from several points of view. Different signalling 
cascades lead to PTX3 production, depending on the cell type and on the stimuli. 
PTX3 promoter contains numerous transcription factor binding sites including Pu1, 
AP-1, NF-κB, SP1 and NF-IL-6 sites. In fibroblasts, AP-1 is involved in the basal 
transcription of PTX3, whereas the NF-κB-binding site is fundamental for the 
transcriptional response to TNFα and IL-1β, even if also Sp1 site seems to be 
important for a complete TNFα and IL-1β response49. In alveolar epithelial cells 
TNFα-induced PTX3 production is mediated by the JNK pathway57. The activation of 
both NF-κB and AP-1 transcription factors is important for the up-regulation of PTX3 
expression in human aortic endothelial cells stimulated with the acute phase protein 
SAA301. In a model of acute myocardial ischemia and reperfusion in mice, the PTX3 
mRNA induction has been linked to the IL-1R-MyD88 pathway56. 
In silico analysis predicted and in vitro experiments confirmed that miR-9 and 
miR-29 control PTX3 mRNA stability directly acting on its 3’ UTR. Whereas miR-9 
activity is dependent on its interaction with PTX3 mRNA, miR-29 controls TNFα-
induced PTX3 expression also through the modulation of the signalling cascade that 
culminates in the PTX3 promoter activation. This last ability of miR-29 is shared with 
other inflammation-related microRNAs induced by pro-inflammatory stimuli in 
monocytes, such as miR-132, miR-146a and miR-155. Whereas miR-132 negatively 
controls both basal and induced PTX3 production, miR-146a and miR-155 
predominant activities are exerted after TNFα and IL-1β-stimulation. These 
observations suggest that miR-132, miR-146a and miR-155 indirectly affect PTX3 
production acting on unidentified regulators of PTX3 biosynthesis. miR-181c data, 
reported here, show how a microRNA-mediated negative regulation on a single 
molecule can be very complex and exerted at several levels. Actually, miR-181c 
operates a down-regulation of PTX3 expression impairing PTX3 promoter activity 
and interfering with the correct folding of PTX3. 
miR-9 has an essential role in mammalian brain development302,303. miR-9 also 
targets the key metastasis-suppressing protein E-cadherin leading to increased cell 
motility and invasiveness in cancer metastasis304. Only in 2008 for the first time miR-
9 has been demonstrated to be involved in the inflammatory response. miR-9 
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transcription is induced in monocytes and PMN by LPS, TNFα and IL-1β and it is 
involved in maintaining constant the levels of the NF-κB transcription factor subunit 
NFKB1/p105, avoiding an exacerbated immune response288. In our experiments miR-
9 does not affect PTX3 promoter activity neither in basal conditions nor after TNFα 
stimulation, suggesting a NF-κB-independent PTX3 production in this experimental 
condition. 
miR-132 has been first linked to neuronal morphogenesis in 2005305 and, only 
one year later, it has been associated to the inflammatory response264. Interestingly, 
miR-132 regulates innate antiviral immunity by targeting the p300 transcriptional co-
activator286. Actually, p300 has been described as a complex protein with several 
functional domains. On one hand, it acts as an adaptor molecule, interacting with 
transcription factors and modulating the expression of target genes transcribed by all 
three RNA polymerases. On the other hand, behaving as a histone acetyltransferase, 
p300 alters the local chromatin structure, allowing transcription. In our experiments, 
miR-132 overexpression resulted in an impaired PTX3 production, whereas any effect 
of miR-132 was reported on PTX3 promoter activity. Hence, we hypothesize a global 
impairment of transcription due to miR-132-dependent p300 down-regulation, exerted 
on both the reporter gene (firefly luciferase) and the house-keeping gene (renilla 
luciferase). This could explain the lack of activity detected on PTX3 promoter, but 
could justify the impairment of PTX3 production observed after miR-132 
overexpression. 
In 2006, Baltimore et al. demonstrated the capacity of miR-146 to negatively 
regulate the immune response. Actually, after its transcriptional induction by LPS, 
miR-146 controls through a feedback mechanism the TLR signalling, directly 
interacting with TRAF6 and IRAK1264. Actually, TRAF6 participates in the IL-
1R/TLR signalling and also in the TNF-induced cascade. The activation of both these 
pathways can lead to the regulation of AP-1 and NF-κB transcription factors306. Also 
IRAK1 has been proposed as a molecule that integrates LPS, TNFα and IL-1β 
signalling pathways307. Hence, TRAF6 and IRAK1 miR-146-mediated targeting could 
be responsible for the PTX3 promoter modulation and for the protein down-regulation 
seen in our experiments. 
miR-155 has been the first oncogenic miRNA to be discovered and its high 
expression has been associated with B-cell and Hodgkin’s lymphomas308. miR-155 
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knockout mouse was the first generated miRNA-deficient animal and it elucidated the 
main importance of miR-155 in driving the immune response283. The TLR/IL-1 
inflammatory pathway has been identified as a general target of miR-155275 that 
interferes also with the TNFR1-mediated signalling309. These abilities of miR-155 
could explain the down-regulation of PTX3 production exerted after TNFα and IL-1β 
stimulation. 
In human monocytes, the concomitant transcriptional induction by pro-
inflammatory stimuli of PTX3 and miR-9, miR-132, miR-146a and miR-155 could be 
a mechanism by which immune cells keep under control the levels of PTX3 and avoid 
an excessive immune response. 
The first description of miR-29 dates back to 2005 when Smirnova and 
colleagues reported a differential expression of miR-29 in different cell types of the 
central nervous system310. One year later, miR-29 and miR-181 have been associated 
to B cell chronic lymphocytic leukaemia (B-CLL). In these cells, both families are 
down-regulated and TCL1 oncogene, a direct target of these microRNAs, is 
consequently up-regulated, facilitating the establishment of a B-CLL aggressive 
form311. Moreover, miR-29 has been associated with the fibrosis of different 
organs312,313. Interestingly, the group of Olson highlighted the role of miR-29 in 
cardiac fibrosis after myocardial infarction. In this context, miR-29 is preferentially 
expressed by the fibroblast population314. miR-29 is also involved in the post-
transcriptional control of proteins of the extracellular matrix315, where PTX3 is 
expressed1. In our hands, miR-29 exerts a direct action on PTX3 mRNA, but it also 
shows an indirect effect on molecules belonging to the PTX3-inducing signalling 
pathway. Actually, miR-29 is regulated and in turn it regulates the Wnt signalling, 
positively modulating osteoblast differentiation316,317. p85α and CDC42 are also 
targets of this miRNA318. p85a is the regulatory subunit of PI3K, a kinase already 
shown to be fundamental in HDL-dependent PTX3 production through the 
lysosphingolipids receptors-PI3K/Akt axis activation in endothelial cells58. CDC42 
belongs to the Rho family GTPases and is known to positively modulate several 
transcription factors, among which AP-1319-321. All these pathways are well 
characterized in inflammatory response and can potentially regulate PTX3 production, 
since miR-29 modulates PTX3 promoter activity. 
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Previously described as a hematopoietic-specific micro-RNA in mouse, miR-181 
has been also detected in normal human B cells, T cells, monocytes and 
granulocytes322. Recently, Luers and colleagues analysed the miRNA profile of 
human primary macrophages differentiated in vitro from peripheral blood CD14+ 
monocytes. miR-181ab have been consistently detected in these cells together with 
miR-29a, miR-132, miR-146a, miR-155 and miR-99b∼7e∼125a cluster323. In the 
same year, Schwind et al. provided the first evidence that the expression of miR-181a 
is associated with the clinical outcome of patients with cytogenetically normal acute 
myeloid leukemia (CN-AML)324. Later, the down-regulation of miR-181ab has been 
correlated to activated B cells and CLL cells325. Among the four members of miR-181 
family, miR-181c is positively regulated by Akt1 in LPS-activated primary murine 
peritoneal macrophages300 where a possible interaction between miR-181 and PTX3 
can be supposed. The highlighted capacity of miR-181c to modulate PTX3 expression 
amplifies the spectrum of PTX3-regulating miRNAs. 
In summary, the results reported in this study emphasize the well-known capacity 
of microRNAs to play the role of fine-tuners of a specific signalling cascade (Fig. 16). 
Basal and TNFα/IL-1β-induced PTX3 expression are regulated by miR-9 and miR-29 
at the post-transcriptional level. PTX3 promoter activation can be modulated by miR-
146a, in both basal and TNFα stimulated conditions, and by miR-29, miR-155 and 
miR-181c after TNFα stimulation. A further level of control is exerted by miR-181c 
through its negative regulation on ERp18 mRNA, interfering presumably with the 
correct folding of PTX3. Since PTX3 is produced by several cell types, future 
experiments are required to validate our results in different cellular contexts: 
monocytes, macrophages and fibroblasts, but also DCs, SMC and EC. It will be also 
important to investigate the PTX3-regulating microRNAs network in vivo. 
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Figure 16 | The complex micro-RNA mediated regulation of PTX3 expression. 
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Concluding remarks 
The work described in this thesis reveals that PTX3 expression can be regulated 
at two different levels by PTX3 SNPs, on one hand, and microRNAs, on the other 
hand. 
Data from the first work of this thesis suggest the possibility to distinguish, at 
least in the Caucasian population, two main groups of subjects according to their 
PTX3 genotypes and, consequently, to their PTX3 basal levels in the blood. We 
hypothesize that these differences could have an impact in the contexts in which 
PTX3 activity is involved. Indeed, the PTX3 haplotypes studied here have been 
associated to innate resistance to selected pathogens, inflammation and female 
fertility. However, this study indicates that even if PTX3 genetic variants affect PTX3 
plasma levels both in healthy subjects and AMI (acute myocardial infarction) patients, 
these variants do not correlate with a different susceptibility to AMI. 
The last work presented here shows for the first time that PTX3 expression can be 
regulated by a plethora of microRNAs at different levels. Some of them act directly 
on PTX3 mRNA, such as miR-9 and miR-29. In parallel, miR-146a, miR-155, miR-
29 and miR-181c control molecules of the signalling pathway for PTX3 transcription. 
Finally, miR-181c down-regulates the expression of ERp18, a molecule involved in 
the correct folding of PTX3. 
Since miRNAs are potential molecular targets of therapeutic approaches, it is 
essential to understand their functions and targets in human cells. Our data report a 
fundamental implication of microRNAs in the control of PTX3 production. Starting 
from these data, further efforts are needed to elucidate in which cell type each 
interaction occurs and the consequences of a disruption of the microRNA complex 
network in terms of PTX3 production and biological effects. 
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